Compounds > chloroquine
Page last updated: 2024-10-24

chloroquine and 2019 Novel Coronavirus Disease

chloroquine has been researched along with 2019 Novel Coronavirus Disease in 418 studies

Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.

Research Excerpts

ExcerptRelevanceReference
"On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning."9.05Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. ( Alhatali, B; Berling, I; Ghannoum, M; Gosselin, S; Hoffman, RS; King, JD; Lavergne, V; Nolin, TD; Roberts, DM; Shepherd, G; Wilson, G, 2020)
" In the absence of evidence-based proven prophylactic or therapeutic options, chloroquine/hydroxychloroquine (CQ/HCQ) patented as first line choice in COVID- 19 treatment, which raised concerns about drug poisoning, especially ocular toxicity."9.05Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19? ( Ahur, MH; Bagheri, M; Eidizadeh, M; Rashe, Z, 2020)
"Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been commonly used for the treatment and prevention of malaria, and the treatment of autoimmune diseases for several decades."9.05Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. ( Chen, ZS; Dong, S; Ke, Z; Lei, ZN; Wu, ZX; Yang, DH; Zhang, L; Zou, C, 2020)
"We found no increased risk of ischemic heart injury or heart failure as a result of administering chloroquine."8.02No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not. ( Beck-Friis, J; Gisslen, M; Leach, S; Omerovic, E; Yilmaz, A; Zeijlon, R, 2021)
"The goal of this systematic review is to assess the published literature for seizure risk with chloroquine or hydroxychloroquine therapy in persons with and without epilepsy."7.96Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. ( Houston, T; Pati, S, 2020)
"Malaria is a threat to human mankind and kills about half a million people every year."6.66Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. ( de Souza, EE; Guimarães, LMF; Krüger, A; Lameu, C; Pillat, MM; Ulrich, H; Wrenger, C, 2020)
" The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart."5.91Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress. ( Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA, 2023)
"Chloroquine has been sporadically used in treating SARS-CoV-2 infection."5.56In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). ( Cui, C; Dong, E; Huang, B; Li, H; Liu, D; Liu, X; Lu, R; Niu, P; Song, C; Tan, W; Yao, X; Ye, F; Zhan, S; Zhang, M; Zhao, L, 2020)
" Some studies have shown that COVID-19 combined with diabetes is an independent risk factor for death or other adverse outcomes."5.56Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. ( Fu, X; Liu, Y; Xie, C, 2020)
" In the absence of evidence-based proven prophylactic or therapeutic options, chloroquine/hydroxychloroquine (CQ/HCQ) patented as first line choice in COVID- 19 treatment, which raised concerns about drug poisoning, especially ocular toxicity."5.05Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19? ( Ahur, MH; Bagheri, M; Eidizadeh, M; Rashe, Z, 2020)
"Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been commonly used for the treatment and prevention of malaria, and the treatment of autoimmune diseases for several decades."5.05Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. ( Chen, ZS; Dong, S; Ke, Z; Lei, ZN; Wu, ZX; Yang, DH; Zhang, L; Zou, C, 2020)
"On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning."5.05Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. ( Alhatali, B; Berling, I; Ghannoum, M; Gosselin, S; Hoffman, RS; King, JD; Lavergne, V; Nolin, TD; Roberts, DM; Shepherd, G; Wilson, G, 2020)
"Since in vitro studies and a preliminary clinical report suggested the efficacy of chloroquine for COVID-19-associated pneumonia, there is increasing interest in this old antimalarial drug."5.05Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. ( Knibbe, CAJ; Peeters, MYM; Smit, C; van den Anker, JN, 2020)
"We found no increased risk of ischemic heart injury or heart failure as a result of administering chloroquine."4.02No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not. ( Beck-Friis, J; Gisslen, M; Leach, S; Omerovic, E; Yilmaz, A; Zeijlon, R, 2021)
"The goal of this systematic review is to assess the published literature for seizure risk with chloroquine or hydroxychloroquine therapy in persons with and without epilepsy."3.96Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. ( Houston, T; Pati, S, 2020)
"Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment."3.96Concentration-dependent mortality of chloroquine in overdose. ( Baud, FJ; Clemessy, JL; Hoglund, RM; Megarbane, B; Tarning, J; Watson, JA; White, NJ, 2020)
"Neither diazepam nor other ligands for benzodiazepine binding sites protect against or attenuate chloroquine cardiotoxicity."3.96Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam. ( Hughes, DA, 2020)
"The safety assessment revealed no adverse effect of the drugs in COVID-19 patients after treatment."3.30Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria. ( Abiola, A; Adeyemo, WL; Agabi, OP; Aina, OO; Ajibaye, O; Akase, IE; Akinbode, GO; Akintan, PE; Amoo, OS; Audu, RA; Bamidele, TA; Bode, C; Busari, AA; David, AN; Esezobor, C; Ezechi, OC; Fadipe, B; Ima-Edomwonyi, E; James, AB; Musa, AZ; Nmadu, N; Okoyenta, CO; Okwuraiwe, AP; Oladele, DA; Olakiigbe, AK; Olopade, OB; Osuolale, KA; Otrofanowei, E; Raheem, TY; Salako, AO; Salako, BL; Tade, T, 2023)
" Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice."3.01How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. ( Brosnan, M; Fairley, JL; Mack, HG; Nikpour, M; Pellegrini, M; Saracino, AM; Wicks, IP, 2023)
"The high prevalence and incidence of coronavirus disease 2019 (COVID-19) underline the importance of searching for a safe and effective treatment for the disease, and drug repositioning is the most rational strategy to achieve this goal in a short period of time."3.01Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. ( Giarolla, J; Parise-Filho, R; Polli, MC; Vassiliades, SV; Vaz, ES, 2023)
"The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir."2.94Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. ( Albuquerque, BC; Alexandre, MAA; Baía-da-Silva, D; Balieiro, AAS; Bassat, Q; Borba, MGS; Brito, M; Brito-Sousa, JD; Croda, J; Daniel-Ribeiro, CT; Fontes, CJ; Guerra, MVF; Hajjar, LA; Lacerda, MVG; Melo, GC; Monteiro, WM; Mourão, MPG; Naveca, FG; Nogueira, ML; Pacheco, AGF; Pinto, RC; Romero, GAS; Sampaio, VS; Santos, JDO; Schwarzbold, A; Siqueira, AM; Val, FFA; Xavier, MS, 2020)
"Since the outbreak of coronavirus disease 2019 (COVID-19) in the late 2019, a variety of antiviral drugs have been used in the first-line clinical trial."2.94[Chloroquine phosphate: therapeutic drug for COVID-19]. ( Mo, L; Zheng, P, 2020)
"Although there is still no consistent evidence about HCQ/CQ retinal toxicity in patients with COVID-19, these possible drug-related retinal adverse events may represent a major safety concern."2.72Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. ( Bassetti, M; Ferro Desideri, L; Nicolò, M; Traverso, CE, 2021)
" The choice of (typically subtherapeutic) dosing regimens, influenced partly by "QT-phobia," varied widely and seems anecdotal without any pharmacologically reliable supporting clinical evidence."2.72Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. ( Shah, RR, 2021)
"Hydroxychloroquine was not significantly associated with mortality: pooled relative risk (RR) 0."2.72Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. ( Fiolet, T; Guihur, A; Mahamat-Saleh, Y; Mulot, M; Peiffer-Smadja, N; Rebeaud, ME, 2021)
" Twenty-four (47%) RCTs did not describe plans to assess safety outcomes; when assessed, safety outcomes were determined in generic terms of total, severe or serious adverse events."2.72Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic. ( Junqueira, DR; Rowe, BH, 2021)
"Chloroquine (CQ) has been repurposed to treat coronavirus disease 2019 (COVID-19)."2.72Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. ( Cai, T; Cui, C; Hou, Z; Li, H; Lin, J; Liu, D; Liu, Q; Wang, X; Xiong, Z; Yan, X; Yao, X; Zhang, S, 2021)
"The whole world is battling through coronavirus disease 2019 (COVID-19) which is a fatal pandemic."2.72Antiviral treatment in COVID-19: which is the most promising?-a narrative review. ( Wen, S; Xu, X; Yadav, AK; Yu, L, 2021)
"Favipiravir has resulted in a higher viral clearance than remdesivir."2.72A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. ( Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M, 2021)
" Nine trials compared HCQ with standard care (7779 participants), and one compared HCQ with placebo (491 participants); dosing schedules varied."2.72Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. ( Chaplin, M; Fletcher, T; Kredo, T; Ryan, H; Singh, B, 2021)
" HCQ group has a significantly higher rate of any adverse event (RR 2."2.72Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. ( Jain, S; Kumar, J; Meena, J; Yadav, A, 2021)
" Authors discretion is to conduct more studies considering the optimal dosing regimen and pharmacokinetics assessment."2.72Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. ( Joshi, G; Poduri, R; Thakur, S, 2021)
" The studies of COVID-19 medicine were involved with eligible end points containing mortality, discharge rate, rate of clinical improvement, and rate of serious adverse events."2.72The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. ( Gao, Z; Gong, H; Li, J; Li, W; Qiu, R; Wang, C; Weng, Y; Xiao, Y; Zhang, Q, 2021)
" However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and candidate drugs currently assessed as therapeutic options for COVID-19."2.72Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. ( Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D, 2021)
"Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system."2.66A current review of COVID-19 for the cardiovascular specialist. ( Bohula, EA; Lang, JP; Morrow, DA; Moura, FA; Siddiqi, HK; Wang, X, 2020)
"Malaria is a threat to human mankind and kills about half a million people every year."2.66Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. ( de Souza, EE; Guimarães, LMF; Krüger, A; Lameu, C; Pillat, MM; Ulrich, H; Wrenger, C, 2020)
"The emergence of coronavirus disease 2019 (COVID-19) is caused by the 2019 novel coronavirus (2019-nCoV)."2.66Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19. ( Al-Bari, AA, 2020)
" The review elaborates the mechanism of action, safety (side effects, adverse effects, toxicity) and details of clinical trials for chloroquine and hydroxychloroquine to benefit the clinicians, medicinal chemist, pharmacologist actively involved in controlling the pandemic and to provide therapeutics for the treatment of COVID-19 infection."2.66A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. ( Masand, N; Patil, VM; Singhal, S, 2020)
"Hydroxychloroquine has been demonstrated to limit the replication of SARS-CoV-2 virus in vitro."2.66Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. ( Akram, J; Klonoff, DC; Meo, SA, 2020)
"Chloroquine has recently been shown to be effective in controlling infection caused by the new Corona virus 2019- nCov (SARS-CoV-2)."2.66Chloroquine in controlling biological infections. ( Baranowska, A; Krawczyk, J; Lengier-Krajewska, M; Płusa, T, 2020)
" However, some of these medications have potential cardiac adverse effects."2.66Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. ( Lazar, S; Naksuk, N; Peeraphatdit, TB, 2020)
"The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019."2.66Is hydroxychloroquine beneficial for COVID-19 patients? ( Agostinis, P; Carafoli, E; Li, X; Melino, G; Rabson, A; Shi, Y; Sun, E; Wang, Y, 2020)
"Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic."2.66Medical treatment options for COVID-19. ( Delang, L; Neyts, J, 2020)
" Long-term use of hydroxychloroquine is the cornerstone in the treatment of several auto-immune disorders."2.66Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. ( Khuroo, MS, 2020)
"As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy."2.66Current status of potential therapeutic candidates for the COVID-19 crisis. ( Hashimoto, K; Xie, B; Zhang, J, 2020)
"Chloroquine has been used to treat malaria for more than 70 years."2.66Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population. ( Cui, C; Hou, Z; Li, H; Liu, D; Tu, S; Yao, X; Zhang, M, 2020)
"During the current coronavirus disease 2019 (COVID-19) pandemic, in vivo and in vitro investigations of these drugs have demonstrated potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."2.66Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals. ( Ahmad, A; Alotaibi, NH; Butt, MH; Khan, YH; Mallhi, TH; Misbah, S, 2020)
"COVID-19 (coronavirus disease 2019) is a public health emergency of international concern."2.66A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. ( Cortegiani, A; Einav, S; Giarratano, A; Ingoglia, G; Ippolito, M, 2020)
" This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD."2.66Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. ( Govil, A; Luckett, K; Miller-Handley, H, 2020)
"Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide."2.66Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. ( Hsueh, PR; Hsueh, SC; Ko, WC; Lai, CC; Liu, YH; Wang, CY; Wang, YH; Yen, MY, 2020)
" The current dosage recommended in clinical treatment is larger than that in previous treatment of malaria and the period of treatment is longer."2.66Trial of Chloroquines in the Treatment of COVID-19 and Its Research Progress in Forensic Toxicology. ( Duan, YJ; Huang, F; Liu, L; Liu, Q; Ren, L; Zhao, SQ; Zhou, YW, 2020)
"To reduce the case-fatality rate among coronavirus disease 2019 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction."2.66Controversial treatments: An updated understanding of the coronavirus disease 2019. ( Dai, Y; Huang, S; Zhang, C; Zheng, F, 2020)
"The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world."2.66The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. ( Li, T; Liu, Z; Qin, Y; Wang, J; Wang, Q; Yan, X; Zeng, X; Zhang, F; Zhang, S; Zhang, W; Zhang, X; Zhao, Y, 2020)
"Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended."2.66Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. ( Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM, 2020)
" Although in some recent studies a clinical improvement in COVID-19 patients has been observed, the clinical efficacy of CQ and HCQ in COVID-19 has yet to be proven with randomized controlled studies, many of which are currently ongoing, also considering pharmacokinetics, optimal dosing regimen, therapeutic level and duration of treatment and taking into account patients with different severity degrees of disease."2.66The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? ( Biasiotto, G; Magro, P; Quiros Roldan, E; Zanella, I, 2020)
"The emergence of coronavirus disease 2019 (COVID-19) in December 2019 has resulted in over 20 million cases and 741,808 deaths globally, affecting more than 200 countries."2.66Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. ( Adewale, OB; Akanbi, MO; Bakare, OO; Fadaka, AO; Klein, A; Madiehe, AM; Meyer, M; Sibuyi, NRS, 2020)
"Due to the coronavirus disease 2019 (COVID-19) pandemic, a wide number of compounds are under scrutiny regarding their antiviral activity, one of them being hydroxychloroquine."2.66[Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic]. ( Baranchuk, A; Barbosa, M; Márquez, MF; Mendoza, I; Nuñez, E; Sosa Liprandi, Á; Wyss Quintana, FS; Zaidel, EJ, 2020)
"Sarcoidosis is an autoinflammatory disease characterized by the diffusion of granulomas in the lungs and other organs."2.66Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis. ( Calender, A; Israel-Biet, D; Pacheco, Y; Valeyre, D, 2020)
"Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world has vehemently worked to develop treatments and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented speed."2.66The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. ( Lee, H; Won, JH, 2020)
"Therapy failure caused by complex population-drug-drug (PDDI) interactions including CYP3A4 can be predicted using mechanistic physiologically-based pharmacokinetic (PBPK) modeling."1.91The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling. ( Alsmadi, MM, 2023)
" The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart."1.91Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress. ( Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA, 2023)
"Chloroquine (CQ) is an antimalarial drug with a growing number of applications as recently demonstrated in attempts to treat Covid-19."1.91Molecular mechanisms in chloroquine-exposed muscle cells elucidated by combined proteomic and microscopic studies. ( Czech, A; Freier, E; Hathazi, D; Phan, V; Preuße, C; Roos, A; Shema, G; Zahedi, RP, 2023)
" A physiologically based pharmacokinetic model with detailed respiratory physiology was used to predict regional airway exposure and optimize dosing regimens."1.72Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections. ( Calvino-Martin, F; Hoeng, J; Kolli, AR, 2022)
"However, coronavirus disease 2019 (COVID-19) treatments, themselves, must be considered as potential catalysts for new-onset neuropsychiatric symptoms in COVID-19 patients."1.72Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect? ( Camejo-Avila, NA; Collado Espinal, IB; Delgado-Noguera, LA; Ferro, C; Flora-Noda, DM; Forero-Peña, DA; Hernandez, MM; Landaeta, ME; Maricuto, AL; Morantes Rodríguez, CG; Mozo Herrera, IP; Páez Paz, J; Paniz-Mondolfi, AE; Perez-Garcia, LA; Sordillo, EM; Velásquez, VL, 2022)
"Over the last few months, coronavirus disease 2019 (COVID-19) pandemic caused by the novel coronavirus SARS-CoV-2 has posed a serious threat to public health on a global scale."1.62Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. ( Alejandro, R; Caprio, M; Fabbri, A; Infante, M; Ricordi, C, 2021)
" Food and Drug Administration Adverse Events Reporting System (FAERS) database to assess HCQ/CQ-associated cardiovascular adverse events (CVAEs) in pre-COVID-19 reports."1.62Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. ( Bomze, D; Boursi, B; Dankner, R; Goldman, A; Hod, H; Maor, E; Meirson, T, 2021)
"To evaluate the susceptibility to coronavirus disease 2019 (COVID-19) in patients with autoimmune conditions treated with antimalarials in a population-based study."1.62Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. ( Bajocchi, G; Boiardi, L; Carrozzi, G; Cassone, G; Costantini, M; Croci, S; Galli, E; Giorgi Rossi, P; Gradellini, F; Mancuso, P; Marata, AM; Muratore, F; Pandolfi, P; Pipitone, N; Reta, M; Salvarani, C; Sandri, G; Viani, N, 2021)
"To compare survival of individuals with coronavirus disease 2019 (COVID-19) treated in hospitals that either did or did not routinely treat patients with hydroxychloroquine or chloroquine."1.62Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. ( Beudel, M; Bomers, MK; Buijs, J; Collard, D; De Haan, LR; De Ruijter, W; Douma, RA; Elbers, PW; Goorhuis, A; Gritters van den Oever, NC; Knarren, LG; Moeniralam, HS; Mostard, RL; Peters, EJ; Quanjel, MJ; Reidinga, AC; Renckens, R; Sikkens, JJ; Van Assen, S; Van Den Bergh, JP; Vlasveld, IN, 2021)
"We included laboratory-confirmed coronavirus disease 2019 (COVID-19) patients, who were hospitalized in Guangzhou Eighth People's Hospital and excluded those who had not received anal swabs for SARS-COV-2 RNA testing."1.62Association between detectable SARS-COV-2 RNA in anal swabs and disease severity in patients with coronavirus disease 2019. ( Cai, W; Cao, Y; Chen, X; Hu, F; Li, F; Li, L; Li, Y; Lin, W; Ou, X; Tang, X; Wen, C; Xie, Z, 2021)
" Food and Drug Administration's Adverse Event Reporting System (FAERS) (>13 million total reports) were used."1.62Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. ( Brown, JD; Cicali, B; Henriksen, CH; Sarayani, A, 2021)
"Chloroquine intoxication is a rare but serious condition due to its cardiac toxicity."1.62Extracorporeal cardiopulmonary resuscitation for severe chloroquine intoxication in a child - a case report. ( Amiet, V; Colombier, S; Ferry, T; Longchamp, D; Natterer, J; Perez, MH; Pfister, R, 2021)
"Disease progression was observed in 18 patients (16."1.62Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital. ( Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W, 2021)
"SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China, in December 2019."1.56Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. ( Ajaz, SJ; Banday, AH; Shameem, SA, 2020)
"Patients showed no signs of overt disseminated intravascular coagulation (DIC) in their laboratory analysis."1.56Severe arterial thromboembolism in patients with Covid-19. ( Buise, MP; Canta, LR; Hendriks, J; Krietemeijer, GM; Lameijer, JRC; Nijziel, MR; Troquay, SAM; van Berckel, MMG; van Houte, J; Yo, LSF, 2020)
" In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ."1.56Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. ( Abagyan, R; Cohen, IV; Issa, MA; Makunts, T; Moumedjian, T, 2020)
"The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients."1.56Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics. ( Alwayn, IPJ; de Fijter, JW; de Vries, APJ; Janson, JA; Meziyerh, S; Moes, DJAR; Reinders, MEJ; van Etten, RW; van Gelder, T; Zwart, TC, 2020)
"SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans."1.56New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? ( Colson, P; Devaux, CA; Raoult, D; Rolain, JM, 2020)
" The author here is proposing to test 5-FU in combination with a number of deoxynucleosides on animal models infected with this Covid-19."1.565-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection. ( Ahmad, SI, 2020)
"Chloroquine has been used worldwide for about 75 years and is listed by the WHO as an essential medicine to treat malaria."1.56Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. ( Abena, PM; Adejumo, P; Bottieau, E; Decloedt, EH; Eholie, SP; Kallay, O; Mills, EJ; Muyembe TamFum, JJ; Nachega, JB; Sam-Agudu, NA; Seydi, M; Suleman, F; Zumla, A, 2020)
" This position statement recommends dosage adjustment for these drugs in the context of renal impairment."1.56Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function. ( Andreoli, MCC; Bastos, K; D'Avila, R; Kraychete, A; Misael, AM; Moura-Neto, JA; Nascimento, MMD; Silva, DRD, 2020)
"To the Editor The Coronavirus disease 2019 (COVID-19) has been declared as a pandemic by World Health Organisation (WHO)."1.56Chloroquine in COVID-19: the evidence. ( Agrawal, S; Gupta, N; Ish, P, 2020)
"Chloroquine has been sporadically used in treating SARS-CoV-2 infection."1.56In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). ( Cui, C; Dong, E; Huang, B; Li, H; Liu, D; Liu, X; Lu, R; Niu, P; Song, C; Tan, W; Yao, X; Ye, F; Zhan, S; Zhang, M; Zhao, L, 2020)
" The potential for the use of smart drug delivery technologies like nanoparticle drones loaded with these phytomedicines to overcome bioavailability limitations and improve therapeutic efficacy are discussed."1.56Potential of Flavonoid-Inspired Phytomedicines against COVID-19. ( Kumar, R; Lowe, H; Lyerly, W; Moore, R; Ngwa, W; Reid, TE; Thompson, D; Toyang, N, 2020)
" Some studies have shown that COVID-19 combined with diabetes is an independent risk factor for death or other adverse outcomes."1.56Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. ( Fu, X; Liu, Y; Xie, C, 2020)
"Chloroquine has been proved clinically effective and can bind to the main protease; this may be the antiviral mechanism of this drug."1.56Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. ( Chen, L; Lan, R; Li, P; Shen, R; Yu, R, 2020)
"In the largest reported cohort of coronavirus disease 2019 patients to date treated with chloroquine/hydroxychloroquine±azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported."1.56Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. ( Beldner, S; Chang, D; Chinitz, J; Epstein, LM; Gabriels, J; Goldner, B; Ismail, H; John, R; Mahmood, E; Makker, P; Mansoor, A; Mitra, R; Mountantonakis, S; Saleh, M; Skipitaris, N; Soo Kim, B; Willner, J, 2020)

Research

Studies (418)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's418 (100.00)2.80

Authors

AuthorsStudies
Gordon, DE1
Jang, GM1
Bouhaddou, M1
Xu, J1
Obernier, K1
White, KM1
O'Meara, MJ1
Rezelj, VV1
Guo, JZ1
Swaney, DL1
Tummino, TA1
Hüttenhain, R1
Kaake, RM1
Richards, AL1
Tutuncuoglu, B1
Foussard, H1
Batra, J1
Haas, K1
Modak, M1
Kim, M1
Haas, P1
Polacco, BJ1
Braberg, H1
Fabius, JM1
Eckhardt, M1
Soucheray, M1
Bennett, MJ1
Cakir, M1
McGregor, MJ1
Li, Q2
Meyer, B1
Roesch, F1
Vallet, T1
Mac Kain, A1
Miorin, L1
Moreno, E1
Naing, ZZC1
Zhou, Y2
Peng, S1
Shi, Y4
Zhang, Z3
Shen, W1
Kirby, IT1
Melnyk, JE1
Chorba, JS1
Lou, K1
Dai, SA1
Barrio-Hernandez, I1
Memon, D1
Hernandez-Armenta, C1
Lyu, J1
Mathy, CJP1
Perica, T1
Pilla, KB1
Ganesan, SJ1
Saltzberg, DJ1
Rakesh, R1
Liu, X4
Rosenthal, SB1
Calviello, L1
Venkataramanan, S1
Liboy-Lugo, J1
Lin, Y2
Huang, XP1
Liu, Y7
Wankowicz, SA1
Bohn, M1
Safari, M1
Ugur, FS1
Koh, C1
Savar, NS1
Tran, QD1
Shengjuler, D1
Fletcher, SJ1
O'Neal, MC1
Cai, Y2
Chang, JCJ1
Broadhurst, DJ1
Klippsten, S1
Sharp, PP1
Wenzell, NA1
Kuzuoglu-Ozturk, D1
Wang, HY1
Trenker, R1
Young, JM1
Cavero, DA1
Hiatt, J1
Roth, TL1
Rathore, U1
Subramanian, A1
Noack, J1
Hubert, M1
Stroud, RM1
Frankel, AD1
Rosenberg, OS1
Verba, KA1
Agard, DA1
Ott, M1
Emerman, M1
Jura, N1
von Zastrow, M1
Verdin, E1
Ashworth, A1
Schwartz, O1
d'Enfert, C1
Mukherjee, S2
Jacobson, M1
Malik, HS1
Fujimori, DG1
Ideker, T1
Craik, CS1
Floor, SN1
Fraser, JS1
Gross, JD1
Sali, A1
Roth, BL1
Ruggero, D1
Taunton, J1
Kortemme, T1
Beltrao, P1
Vignuzzi, M1
García-Sastre, A1
Shokat, KM1
Shoichet, BK1
Krogan, NJ1
Jeon, S1
Ko, M1
Lee, J2
Choi, I1
Byun, SY1
Park, S2
Shum, D1
Kim, S2
Choudhry, N1
Zhao, X2
Xu, D2
Zanin, M1
Chen, W3
Yang, Z1
Chen, J3
Pillaiyar, T1
Wendt, LL1
Manickam, M1
Easwaran, M1
de Jesus, JPA1
Assis, LC1
de Castro, AA1
da Cunha, EFF1
Nepovimova, E1
Kuca, K1
de Castro Ramalho, T1
de Almeida La Porta, F1
Mendoza-Pinto, C1
García-Carrasco, M1
Munguía Realpozo, P1
Méndez-Martínez, S1
Mou, Q1
Yang, YW1
Chen, L5
Fang, T1
Yao, YC1
Du, ZQ1
Yang, CX1
Han, F1
Mo, M1
Wang, C6
Yang, Y2
Wu, J2
Jia, Q3
Fu, J3
Liang, P3
Wang, S6
Wang, Y8
Zhang, X7
Zhou, H3
Zhang, L8
Lv, Y3
Han, S3
Forero-Peña, DA1
Hernandez, MM1
Mozo Herrera, IP1
Collado Espinal, IB1
Páez Paz, J1
Ferro, C1
Flora-Noda, DM1
Maricuto, AL1
Velásquez, VL1
Camejo-Avila, NA1
Sordillo, EM1
Delgado-Noguera, LA1
Perez-Garcia, LA1
Morantes Rodríguez, CG1
Landaeta, ME1
Paniz-Mondolfi, AE1
Batiha, GE1
Shaheen, HM1
Al-Kuraishy, HM1
Teibo, JO1
Akinfe, OA1
Al-Garbee, AI1
Teibo, TKA1
Kabrah, SM1
Zhao, H4
Lu, L1
Peng, Z2
Chen, LL1
Meng, X1
Zhang, C2
Ip, JD2
Chan, WM2
Chu, AW1
Chan, KH1
Jin, DY1
Chen, H4
Yuen, KY2
To, KK1
Kolli, AR1
Calvino-Martin, F1
Hoeng, J1
Boretti, A1
Katin, KP1
Kochaev, AI1
Kaya, S1
El-Hajjaji, F1
Maslov, MM1
Beeraka, NM1
Tulimilli, SV1
Greeshma, MV1
Dallavalasa, S1
Zhang, Y9
Xiao, W1
Fan, R1
Zhao, D1
Bettadapura, ADS1
Nataraj, SM1
Madhunapantula, SV1
Liu, J3
Choi, MY1
Weber, B1
Stevens, E1
Guan, H3
Ellrodt, J1
Oakes, E1
Di Carli, M1
Tedrow, U1
Sauer, W1
Costenbader, KH1
Singh, B2
Ryan, H2
Kredo, T2
Chaplin, M2
Fletcher, T2
Gnegel, G2
Häfele-Abah, C2
Neci, R2
Heide, L2
Fairley, JL1
Nikpour, M1
Mack, HG1
Brosnan, M1
Saracino, AM1
Pellegrini, M2
Wicks, IP1
Khabyah, AA1
Jamil, MK1
Koam, ANA1
Javed, A1
Azeem, M1
Moraes, RR1
Correa, MB1
Martins-Filho, PR1
Lima, GS1
Demarco, FF1
Alsmadi, MM1
Abdullaev, SP3
Vihrev, DV3
Shatokhin, MN3
Teodorovich, OV3
Phan, V1
Hathazi, D1
Preuße, C1
Czech, A1
Freier, E1
Shema, G1
Zahedi, RP1
Roos, A1
Mizuta, S1
Mosaddeque, F1
Tun, MMN1
Teklemichael, AA1
Taniguchi, M1
Hosokawa, M1
Yamaguchi, T1
Makau, J1
Huy, NT1
Mizukami, S1
Nishida, N1
Morita, K1
Hirayama, K2
Hu, LY1
Yuan, Y1
Wen, ZX1
Hu, YY1
Yin, MM1
Hu, YJ1
Wang, X15
Burdzhiev, NT1
Hu, H1
Li, Y11
Li, J11
Lozanova, VV1
Kandinska, MI1
Wang, M2
Lucchetta, R1
Matuoka, JY1
Oliveira Junior, HA1
Oliveira, G1
Cavalcanti, AB1
Azevedo, L1
Berwanger, O1
Lopes, RD2
Rosa, RG1
Veiga, VC1
Avezum, Á1
Vaz, ES1
Vassiliades, SV1
Giarolla, J1
Polli, MC1
Parise-Filho, R1
Seydi, E1
Hassani, MK1
Naderpour, S1
Arjmand, A1
Pourahmad, J1
Aït Moussa, L1
Tebaa, A1
Alj, L1
Sefiani, H1
Meski, FZ1
Khattabi, A1
Soulaymani Bencheikh, R1
Abdelmageed, N1
Twafik, WA1
Morad, OA1
Haridy, M1
Hassan, R1
Ahmed, M1
El-Zorba, HY1
El-Banna, HA1
Seddek, AL1
Ghallab, A1
Morad, SAF1
Olukosi, AY1
Fowora, M1
Adeneye, AK1
Chukwu, E1
Aina, O1
Ajibaye, O2
James, A1
Gab-Okafor, C1
Holdbrooke, SA1
Ohihoin, EN1
Musa, AZ2
Amoo, O1
Showemimo, O1
Afolabi, B1
Ezechi, OC2
Salako, BL2
Alkafaas, SS1
Abdallah, AM1
Hussien, AM1
Bedair, H1
Abdo, M1
Ghosh, S1
Elkafas, SS1
Apollon, W1
Saki, M1
Loutfy, SA1
Onyeaka, H1
Hessien, M1
Diesendorf, V1
Roll, V1
Geiger, N1
Fähr, S1
Obernolte, H1
Sewald, K1
Bodem, J1
Poncelet, C1
Porcher, R1
Nguyen, YL1
Ng, JPL1
Xiao Yun, Y1
Adnan Nasim, A1
Gianoncelli, A1
Yuan Kwan Law, B1
Ribaudo, G1
Kam Wai Wong, V1
Coghi, P1
Souza-Silva, MVR1
Pereira, DN1
Pires, MC1
Vasconcelos, IM1
Schwarzbold, AV1
Vasconcelos, DH1
Pereira, EC1
Manenti, ERF1
Costa, FR1
Aguiar, FC1
Anschau, F1
Bartolazzi, F1
Nascimento, GF1
Vianna, HR1
Batista, JDL1
Machado-Rugolo, J1
Ruschel, KB1
Ferreira, MAP1
Oliveira, LS1
Menezes, LSM1
Ziegelmann, PK1
Tofani, MGT1
Bicalho, MAC1
Nogueira, MCA1
Guimarães-Júnior, MH1
Aguiar, RLO1
Rios, DRA1
Polanczyk, CA1
Marcolino, MS1
Aina, OO1
Busari, AA1
Oladele, DA1
Esezobor, C1
Akase, IE1
Okwuraiwe, AP1
Okoyenta, CO1
Otrofanowei, E1
James, AB1
Bamidele, TA1
Olopade, OB1
Salako, AO1
Agabi, OP1
Olakiigbe, AK1
Akintan, PE1
Amoo, OS1
Ima-Edomwonyi, E1
Raheem, TY1
David, AN1
Akinbode, GO1
Nmadu, N1
Osuolale, KA1
Fadipe, B1
Abiola, A1
Tade, T1
Audu, RA1
Adeyemo, WL1
Bode, C1
Sarkarai, D1
Desikan, K1
Cao, R1
Yang, X5
Xu, M1
Shi, Z1
Hu, Z1
Zhong, W2
Xiao, G1
Maxmen, A1
Gao, J4
Tian, Z1
Zhang, Q5
Qi, C1
Shen, L1
Colson, P2
Rolain, JM2
Lagier, JC1
Brouqui, P1
Raoult, D3
Touret, F1
de Lamballerie, X1
Dong, L2
Hu, S3
Yao, X3
Ye, F1
Zhang, M6
Cui, C3
Huang, B1
Niu, P1
Zhao, L1
Dong, E1
Song, C1
Zhan, S1
Lu, R1
Li, H8
Tan, W1
Liu, D3
Zhu, LQ1
Nau, JY1
Devaux, CA1
Cortegiani, A3
Ingoglia, G3
Ippolito, M3
Giarratano, A2
Einav, S3
Lai, CC1
Liu, YH1
Wang, CY1
Wang, YH1
Hsueh, SC1
Yen, MY1
Ko, WC1
Hsueh, PR1
Sahraei, Z1
Shabani, M1
Shokouhi, S1
Saffaei, A1
Duan, Y1
Zhu, HL1
Zhou, C1
Hu, TY1
Frieman, M1
Wolfram, J1
Guastalegname, M1
Vallone, A1
Duan, YJ1
Liu, Q3
Zhao, SQ1
Huang, F1
Ren, L1
Liu, L3
Zhou, YW1
Carradori, S1
Lecuit, M1
Kupferschmidt, K2
Cohen, J1
Huang, S1
Zheng, F2
Dai, Y1
Zhang, W1
Zhao, Y4
Zhang, F3
Wang, Q3
Li, T2
Liu, Z4
Wang, J6
Qin, Y1
Yan, X2
Zeng, X1
Zhang, S6
Agrawal, S2
Goel, AD1
Gupta, N2
Ish, P2
Yazdany, J1
Kim, AHJ2
Georgiev, T1
Hong, W1
Huang, M2
Tang, T1
Pang, P1
Li, M2
Ma, R1
Lu, J6
Shu, J1
You, Y1
Chen, B2
Liang, J1
Hong, Z2
Kong, L1
Qin, D1
Pei, D1
Xia, J2
Jiang, S2
Shan, H1
Spinelli, FR2
Ceccarelli, F2
Di Franco, M3
Conti, F3
Keshtkar-Jahromi, M1
Bavari, S1
Marmor, MF2
Marotto, D1
Sarzi-Puttini, P1
Fantini, J1
Di Scala, C1
Chahinian, H1
Yahi, N1
Barlow, A1
Landolf, KM1
Barlow, B1
Yeung, SYA1
Heavner, JJ1
Claassen, CW1
Heavner, MS1
Moore, N1
Monteiro, WM3
Brito-Sousa, JD2
Baía-da-Silva, D2
Melo, GC2
Siqueira, AM2
Val, F1
Daniel-Ribeiro, CT2
Guimarães Lacerda, MV1
Juurlink, DN1
Ferner, RE1
Aronson, JK1
Jakhar, D1
Kaur, I1
Jaffe, S1
Serafin, MB1
Bottega, A1
Foletto, VS1
da Rosa, TF1
Hörner, A1
Hörner, R1
Shah, S1
Das, S3
Jain, A1
Misra, DP1
Negi, VS1
Sanders, JM1
Monogue, ML1
Jodlowski, TZ1
Cutrell, JB1
Guidon, AC1
Amato, AA1
Rome, BN1
Avorn, J1
Şimşek Yavuz, S1
Ünal, S1
Gendrot, M1
Javelle, E1
Clerc, A1
Savini, H1
Pradines, B1
El Boussadani, B1
Benajiba, C1
Aajal, A1
Ait Brik, A1
Ammour, O1
El Hangouch, J1
Oussama, O1
Oussama, B1
Tahiri, N1
Raissuni, Z1
Zhao, M1
Smit, C1
Peeters, MYM1
van den Anker, JN1
Knibbe, CAJ1
Principi, N1
Esposito, S1
Rathi, S1
Kalantri, A1
Kalantri, S1
Lentini, G1
Cavalluzzi, MM1
Habtemariam, S2
Perricone, C1
Triggianese, P1
Bartoloni, E1
Cafaro, G1
Bonifacio, AF1
Bursi, R1
Perricone, R1
Gerli, R1
Moiseev, S1
Avdeev, S1
Brovko, M1
Novikov, P1
Fomin, V1
Khunti, S1
Khunti, N1
Seidu, S1
Khunti, K1
Dondorp, AM1
Hayat, M1
Aryal, D1
Beane, A1
Schultz, MJ1
Licciardi, F1
Giani, T1
Baldini, L1
Favalli, EG1
Caporali, R1
Cimaz, R1
Embi, MN1
Ganesan, N1
Sidek, HM1
Abena, PM1
Decloedt, EH2
Bottieau, E1
Suleman, F1
Adejumo, P1
Sam-Agudu, NA2
Muyembe TamFum, JJ1
Seydi, M1
Eholie, SP1
Mills, EJ2
Kallay, O1
Zumla, A2
Nachega, JB2
Manning, TJ1
Thomas-Richardson, J1
Cowan, M1
Beard, T1
Sarayani, A1
Cicali, B1
Henriksen, CH1
Brown, JD1
Jiang, Y2
Xi, H1
Liu, C6
Qu, F1
Feng, X2
Fihn, SD1
Perencevich, E1
Bradley, SM1
Borba, MGS1
Val, FFA1
Sampaio, VS2
Alexandre, MAA1
Brito, M1
Mourão, MPG1
Guerra, MVF1
Hajjar, LA1
Pinto, RC1
Balieiro, AAS1
Pacheco, AGF1
Santos, JDO1
Naveca, FG1
Xavier, MS1
Schwarzbold, A1
Croda, J1
Nogueira, ML1
Romero, GAS1
Bassat, Q1
Fontes, CJ1
Albuquerque, BC1
Lacerda, MVG1
Alexander, PE1
Debono, VB1
Mammen, MJ1
Iorio, A1
Aryal, K1
Deng, D1
Brocard, E1
Alhazzani, W1
Millán-Oñate, J1
Millan, W1
Mendoza, LA1
Sánchez, CG1
Fernandez-Suarez, H1
Bonilla-Aldana, DK1
Rodríguez-Morales, AJ1
Funck-Brentano, C1
Salem, JE1
Nguyen, LS1
Drici, MD1
Roden, DM1
Cheng, CY2
Lee, YL1
Chen, CP2
Lin, YC2
Liu, CE1
Liao, CH1
Cheng, SH2
Ledford, H2
Capoluongo, ED1
Amato, F1
Castaldo, G1
Zhang, J6
Xie, B1
Hashimoto, K1
Iyer, M1
Jayaramayya, K1
Subramaniam, MD1
Lee, SB2
Dayem, AA1
Cho, SG1
Vellingiri, B1
Ahsan, W1
Javed, S1
Bratty, MA1
Alhazmi, HA1
Najmi, A1
Meziyerh, S1
Zwart, TC1
van Etten, RW1
Janson, JA1
van Gelder, T1
Alwayn, IPJ1
de Fijter, JW1
Reinders, MEJ1
Moes, DJAR1
de Vries, APJ1
Askanase, AD1
Khalili, L1
Buyon, JP1
Sargin, G1
Yavaşoğlu, Sİ1
Yavasoglu, I1
Saleh, M1
Gabriels, J1
Chang, D1
Soo Kim, B1
Mansoor, A1
Mahmood, E1
Makker, P1
Ismail, H1
Goldner, B1
Willner, J1
Beldner, S1
Mitra, R1
John, R1
Chinitz, J1
Skipitaris, N1
Mountantonakis, S1
Epstein, LM1
Liu, M1
Caputi, TL1
Dredze, M1
Kesselheim, AS2
Ayers, JW1
Jeevaratnam, K1
Javelot, H1
El-Hage, W1
Meyer, G1
Becker, G1
Michel, B1
Hingray, C1
Kang, Y1
Chen, T1
Mui, D1
Ferrari, V1
Jagasia, D1
Scherrer-Crosbie, M1
Chen, Y7
Han, Y1
Chary, MA1
Barbuto, AF1
Izadmehr, S1
Hayes, BD1
Burns, MM1
Monzani, A1
Genoni, G1
Scopinaro, A1
Pistis, G1
Kozel, D1
Secco, GG1
Chowdhury, MS1
Rathod, J1
Gernsheimer, J1
Shader, RI1
Delang, L1
Neyts, J1
Xu, CY1
Lu, SD1
Ye, X1
Cao, MY1
Xu, GD1
Yu, Q1
Qian, JX1
Zeng, G1
Svensson, M1
Seftel, MD1
Nath, KA1
D'Acquarica, I1
Agranat, I1
Naksuk, N1
Lazar, S1
Peeraphatdit, TB1
Meo, SA1
Klonoff, DC1
Akram, J2
Lucchino, B1
Wong, A1
Szekely, Y1
Lichter, Y1
Shrkihe, BA1
Bruck, H1
Oster, HS1
Viskin, S1
Piszczatoski, CR1
Powell, J1
Yu, R1
Lan, R1
Shen, R2
Li, P2
Kuipers, MT1
van Zwieten, R1
Heijmans, J1
Rutten, CE1
de Heer, K1
Kater, AP1
Nur, E1
Coumou, J1
de Vries, PJ1
Annangi, S1
Gadebusch Bondio, M1
Marloth, M1
Anastasiou, IA1
Eleftheriadou, I1
Tentolouris, A1
Tsilingiris, D1
Tentolouris, N1
Hauk, C1
Mutombo, G1
Nyaah, F1
Wistuba, D1
Palmeira, VA1
Costa, LB1
Perez, LG1
Ribeiro, VT1
Lanza, K1
Silva, ACSE1
Reihani, H1
Ghassemi, M1
Mazer-Amirshahi, M1
Aljohani, B1
Pourmand, A1
Derwand, R1
Scholz, M1
Vouri, SM1
Thai, TN1
Winterstein, AG1
Gegúndez-Fernández, JA1
Zarranz-Ventura, J1
Garay-Aramburu, G1
Muñoz-Negrete, FJ1
Mendicute Del Barrio, J1
Pablo-Júlvez, L1
García-Delpech, S1
López-Alemany, A1
Arnalich-Montiel, F1
Cordero-Coma, M1
Cárceles, JA1
Hughes, DA1
Asensio, E1
Acunzo, R1
Uribe, W1
Saad, EB1
Sáenz, LC1
Patil, VM1
Singhal, S1
Masand, N1
Gevers, S1
Kwa, MSG1
Wijnans, E1
van Nieuwkoop, C1
Estella, Á1
Garnacho-Montero, J1
Marto, N1
Monteiro, EC1
Kucharz, EJ1
Zhai, MZ1
Lye, CT1
Quiros Roldan, E1
Biasiotto, G1
Magro, P1
Zanella, I1
Oren, O1
Yang, EH1
Gluckman, TJ1
Michos, ED1
Blumenthal, RS1
Gersh, BJ1
Edelstein, CL1
Venkatachalam, MA1
Dong, Z2
Ahmad, SI1
Yahya, AS1
Khawaja, S1
Chukwuma, J1
Zaidel, EJ1
Wyss Quintana, FS1
Sosa Liprandi, Á1
Mendoza, I1
Márquez, MF1
Nuñez, E1
Barbosa, M1
Baranchuk, A1
Tripathy, S1
Dassarma, B1
Roy, S1
Chabalala, H1
Matsabisa, MG1
Thangaraju, P1
Gurunthalingam, MP1
Venkatesan, S1
Thangaraju, E1
Teherán, AA1
Camero, G1
Hernández, C1
Perez-Garcia, L1
Gúzman, R1
Paniz-Mondolfi, A1
Ramírez, JD1
Gao, Q1
Hernandez, AV5
Roman, YM3
Pasupuleti, V3
Barboza, JJ3
White, CM4
Hodkinson, B1
Singh, P1
Gcelu, A1
Bautista-Molano, W1
Pons-Estel, G1
Alpízar-Rodríguez, D1
Kamp, TJ1
Hamdan, MH1
January, CT1
Vaduganathan, M1
van Meijgaard, J1
Mehra, MR1
Joseph, J1
O'Donnell, CJ1
Warraich, HJ1
Rodrigo, C1
Fernando, SD1
Rajapakse, S1
Lahfaoui, M1
Azizi, M1
Elbakkaoui, M1
El Amrani, R1
Kamaoui, I1
Benhaddou, H1
Ektorp, E1
Weehuizen, JM2
Hoepelman, AIM2
Askin, L1
Tanrıverdi, O1
Askin, HS1
Liu, W2
Zhou, P1
Chen, K2
Ye, Z1
Liu, F1
Li, X15
He, N1
Wu, Z1
Gong, X1
Tang, Q1
Du, X2
Ying, Y1
Xu, X4
Shen, N1
Couban, RJ1
Ibrahim, QI1
Guyatt, G1
Zhai, S1
Ibáñez, S1
Martínez, O1
Valenzuela, F1
Silva, F1
Valenzuela, O1
Sun, J3
Fan, X1
Han, Q1
Lang, JP1
Moura, FA1
Siddiqi, HK1
Morrow, DA1
Bohula, EA1
Mvumbi, DM1
Gouveia, CC1
Campos, L1
Bimonte, S1
Crispo, A1
Amore, A1
Celentano, E1
Cuomo, A1
Cascella, M1
Ata, F1
Almasri, H1
Sajid, J1
Yousaf, Z1
Dos Reis Neto, ET1
Kakehasi, AM1
de Medeiros Pinheiro, M1
Ferreira, GA1
Marques, CDL1
da Mota, LMH1
Dos Santos Paiva, E1
Pileggi, GCS1
Sato, EI1
Reis, APMG1
Xavier, RM1
Provenza, JR1
Nowak, JK3
Walkowiak, J3
Brest, P1
Benzaquen, J1
Klionsky, DJ3
Hofman, P1
Mograbi, B1
Bonam, SR1
Muller, S1
Bayry, J1
Medeiros-Domingo, A1
Carrasco, OF1
Berni-Betancourt, A1
Pan, X2
Yang, L1
Chen, D2
Peng, C1
Medina, MT1
Moncada, SS1
Santillán-García, A1
Bravo-Jeria, R1
Verdugo-Paiva, F1
Rada, G1
Stojkovic-Filipovic, J1
Bosic, M1
Ngwa, W1
Kumar, R1
Thompson, D1
Lyerly, W1
Moore, R1
Reid, TE1
Lowe, H1
Toyang, N1
Qaseem, A2
Yost, J2
Etxeandia-Ikobaltzeta, I2
Miller, MC1
Abraham, GM1
Obley, AJ1
Forciea, MA1
Jokela, JA1
Humphrey, LL2
Al-Bari, AA1
Huang, Y2
Cai, C1
Zang, J1
Xie, J1
Zhan, T1
Huang, K1
Hu, ZY1
Deng, Y1
Xie, Y1
Chee, YJ1
Tan, SK1
Yeoh, E1
Pati, S1
Houston, T1
Fassihi, SC1
Nabar, NR1
Fassihi, R1
Abrams-Downey, A1
Saabiye, J1
Vidaurrazaga, M1
Płusa, T1
Lengier-Krajewska, M1
Baranowska, A1
Krawczyk, J1
Mubagwa, K1
Timerbulatov, SV1
Timerbulstov, MV1
Gainullina, EN1
Gafarova, AR1
Timerbulatov, VM1
Wu, L1
O'Kane, AM1
Peng, H1
Bi, Y1
Motriuk-Smith, D1
Ren, J1
Kazama, I1
Iannaccone, G1
Scacciavillani, R1
Del Buono, MG1
Camilli, M1
Ronco, C1
Lavie, CJ1
Abbate, A1
Crea, F1
Massetti, M1
Aspromonte, N1
Million, M1
Roussel, Y1
Cirino, G1
Ahluwalia, A1
Guzman-Prado, Y1
Shehab, N1
Lovegrove, M1
Budnitz, DS1
Oscanoa, TJ1
Romero-Ortuno, R1
Carvajal, A1
Savarino, A2
Chen, X4
Geiger, JD1
Naghipour, S1
Ghodousi, M1
Rahsepar, S1
Elyasi, S1
Martinez, GP1
Zabaleta, ME1
Di Giulio, C1
Charris, JE1
Mijares, MR1
Biguetti, C1
Marrelli, MT1
Brotto, M1
Watson, JA2
Tarning, J2
Hoglund, RM2
Baud, FJ1
Megarbane, B2
Clemessy, JL1
White, NJ2
Sachdev, U1
Ferrari, R1
Cui, X2
Pius, A1
Sahu, A1
Reynolds, M1
Liao, H1
Sun, P1
Shinde, S1
Ambrosio, F1
Shiva, S1
Loughran, P1
Scott, M1
Shang, Y1
Zhu, H2
Chen, G3
Liu, S1
Agostinis, P1
Rabson, A1
Melino, G2
Carafoli, E3
Sun, E1
Sharma, A1
Kumar Sharma, S1
Bucci, E1
Bhattacherjee, A1
Das, G1
Santos-Moreno, P1
Buitrago-Garcia, D1
Villarreal, L1
Aza, A1
Cabrera, M1
Rivero, W1
Rojas-Villarraga, A1
Liew, JW1
Graef, ER1
Sparks, JA2
Kim, AH1
Hou, Z2
Tu, S1
Hsia, BC1
Greige, N1
Quiroz, JA1
Khokhar, AS1
Daily, J1
Di Biase, L1
Ferrick, KJ1
Fisher, JD1
Krumerman, A1
Osama El-Gendy, A1
Saeed, H1
Ali, AMA1
Zawbaa, HM1
Gomaa, D1
Harb, HS1
Madney, YM1
Osama, H1
Abdelrahman, MA1
Abdelrahim, MEA1
Reuter, H1
Allwood, B1
Parker, A1
Koegelenberg, CFN1
Blockman, M1
Taljaard, J1
Kouzy, R1
Abi Jaoude, J1
Garcia Garcia, CJ1
El Alam, MB1
Taniguchi, CM1
Ludmir, EB1
Torres-Costa, S1
Lima-Fontes, M1
Falcão-Reis, F1
Falcão, M1
Belizário, JE1
Doboszewska, U1
Wlaź, P1
Nowak, G1
Młyniec, K1
Lin, W2
Xie, Z1
Li, L2
Wen, C1
Cao, Y2
Ou, X1
Hu, F1
Li, F2
Tang, X2
Cai, W1
Schrezenmeier, EV1
Burmester, GR1
Eckardt, KU1
Dörner, T1
Pizzorno, A1
Padey, B1
Dubois, J1
Julien, T1
Traversier, A1
Dulière, V1
Brun, P1
Lina, B1
Rosa-Calatrava, M1
Terrier, O1
Hazra, S1
Chaudhuri, AG1
Tiwary, BK1
Chakrabarti, N1
Iozzo, P1
Pillat, MM1
Krüger, A1
Guimarães, LMF1
Lameu, C1
de Souza, EE1
Wrenger, C1
Ulrich, H1
Jankowska, EA1
Sierpiński, R1
Tkaczyszyn, M1
Drozd, M1
Szachniewicz, J1
Duda-Sikuła, M1
Knysz, B1
Simon, K1
Szenborn, L1
Ponikowski, P1
Khuroo, MS1
Sultan, S1
Acharya, Y1
Banday, AH1
Shameem, SA1
Ajaz, SJ1
Infante, M1
Ricordi, C1
Alejandro, R1
Caprio, M1
Fabbri, A1
Hoffmann, M1
Mösbauer, K1
Hofmann-Winkler, H1
Kaul, A1
Kleine-Weber, H1
Krüger, N1
Gassen, NC1
Müller, MA1
Drosten, C1
Pöhlmann, S1
Javorac, D1
Grahovac, L1
Manić, L1
Stojilković, N1
Anđelković, M1
Bulat, Z1
Đukić-Ćosić, D2
Curcic, M2
Djordjevic, AB1
Paliani, U1
Cardona, A1
Silva Arouche, TD1
Reis, AF1
Martins, AY1
S Costa, JF1
Carvalho Junior, RN1
J C Neto, AM1
Koren, G1
Korn, L1
Tang, D1
Zhang, R1
Kang, R1
Han, YJ1
Ren, ZG1
Li, XX1
Yan, JL1
Ma, CY1
Wu, DD1
Ji, XY1
Islam, M1
Lebin, JA2
LeSaint, KT2
Braz, HLB1
Silveira, JAM1
Marinho, AD1
de Moraes, MEA1
Moraes Filho, MO1
Monteiro, HSA1
Jorge, RJB1
Senna, G1
Caminati, M1
Castells, M1
Gao, G1
Wang, A1
Qian, F1
Chen, M1
Yu, F1
Ma, X1
Zhao, T2
Chen, Z2
Zou, L1
Dai, L1
Putman, M1
Chock, YPE1
Tam, H1
Sattui, SE1
Berenbaum, F1
Danila, MI1
Korsten, P1
Sanchez-Alvarez, C1
Coates, LC1
Palmerlee, C1
Peirce, A1
Jayatilleke, A1
Johnson, SR1
Kilian, A1
Liew, J1
Prokop, LJ1
Murad, MH2
Grainger, R1
Wallace, ZS1
Duarte-García, A1
Grabbe, S1
Beissert, S1
Enk, A1
Vollaard, A1
Gieling, EM1
van der Linden, PD1
Sinha, B1
de Boer, MGJ1
Norinder, U1
Tuck, A1
Norgren, K1
Munic Kos, V1
Salvarani, C1
Mancuso, P1
Gradellini, F1
Viani, N1
Pandolfi, P1
Reta, M1
Carrozzi, G1
Sandri, G1
Bajocchi, G1
Galli, E1
Muratore, F1
Boiardi, L1
Pipitone, N1
Cassone, G1
Croci, S1
Marata, AM1
Costantini, M1
Giorgi Rossi, P1
Tarek, M1
Lameijer, JRC1
van Houte, J1
van Berckel, MMG1
Canta, LR1
Yo, LSF1
Nijziel, MR1
Krietemeijer, GM1
Troquay, SAM1
Buise, MP1
Hendriks, J1
Bagheri, M2
Rashe, Z1
Ahur, MH1
Eidizadeh, M1
Weston, S1
Coleman, CM1
Haupt, R1
Logue, J1
Matthews, K1
Reyes, HM1
Weiss, SR1
Frieman, MB1
De Franceschi, L1
Costa, E1
Dima, F1
Morandi, M1
Olivieri, O1
Gentile, D1
Fuochi, V1
Rescifina, A1
Furneri, PM1
Halm, MA1
Fadaka, AO1
Sibuyi, NRS1
Adewale, OB1
Bakare, OO1
Akanbi, MO1
Klein, A1
Madiehe, AM1
Meyer, M1
Podlasin, RB1
Kowalska, JD1
Pihowicz, A1
Wojtycha-Kwaśnica, B1
Thompson, M1
Dyda, T1
Czeszko-Paprocka, H1
Horban, A1
Sbidian, E1
Penso, L1
Herlemont, P1
Botton, J1
Baricault, B1
Semenzato, L1
Drouin, J1
Weill, A1
Dray-Spira, R1
Zureik, M1
Fiolet, T2
Guihur, A2
Rebeaud, ME2
Mulot, M2
Peiffer-Smadja, N2
Mahamat-Saleh, Y2
Uzunova, K1
Filipova, E1
Pavlova, V1
Vekov, T1
Calender, A1
Israel-Biet, D1
Valeyre, D1
Pacheco, Y1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X2
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M2
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Zhou, L3
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y2
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tao, F1
Xiang, W1
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Shan, A1
Wu, M2
Ma, Q1
Zhang, E1
Xue, F1
Deng, L1
Yan, Z2
Meng, J1
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Ren, Y1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Zhou, X3
Wang, W1
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Wu, X1
Li, W4
Wu, W1
Du, F1
Ji, H1
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C2
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Jung, YJ1
Koh, J1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S2
Zhang, H2
Yang, T3
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liang, C1
Yang, H1
Song, Y1
Yu, K2
Zhu, C1
Huang, Z3
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Rathore, MG1
Reddy, K1
Shin, SH1
Ma, WY1
Bode, AM1
Mu, W1
Gao, F1
Qi, Y1
Lu, H1
Cai, X1
Ji, RY1
Hou, Y4
Tian, J2
Ying, S1
Tan, M1
Feng, G1
Kuang, Y2
Wu, D4
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z3
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Lu, Y1
Xi, J1
Li, C1
Hu, X1
Wei, H1
Wang, Z2
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Lyu, Y1
Huang, J2
Yu, N1
Wen, Z1
Hou, H1
Gupta, A2
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D3
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R2
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Alexander, R1
Mondal, A1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J2
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y2
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H2
He, Z1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Duong, F1
Kong, W1
Chang, JH1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Shao, Z1
Yuan, C1
Wu, Y2
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z2
Wang, T1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P2
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J2
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ2
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J2
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P2
Nabi, M1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Jeong, HJ1
Min, S1
Chae, H1
Lee, G1
Namgoong, SK1
Jeong, K1
Watanabe, LM1
Pires, IF1
Noronha, NY1
Pinhel, MAS1
Nonino, CB1
Moura-Neto, JA1
Misael, AM1
Silva, DRD1
D'Avila, R1
Andreoli, MCC1
Kraychete, A1
Bastos, K1
Nascimento, MMD1
Fatima, U1
Rizvi, SSA1
Fatima, S1
Hassan, MI1
Chan, XHS1
Cheah, PY1
Mo, L1
Zheng, P1
Guo, F1
Taleb, SJ1
Tong, M1
Shang, D1
Lei, ZN1
Wu, ZX1
Dong, S1
Yang, DH1
Ke, Z1
Chen, ZS1
Danjuma, MI1
Sinha, U1
Fatima, H1
Mohamed, MFH1
Nathoe, H1
Trevenzoli, M1
Guarnaccia, A1
Alberici, I1
Fassan, M1
Di Meco, E1
Farinati, F1
Cattelan, AM1
Baralić, K1
Jorgovanović, D1
Živančević, K1
Antonijević Miljaković, E1
Antonijević, B1
Buha Djordjevic, A1
Wang, N1
Liu, R2
Meng, L1
He, H1
Ding, Y2
Lu, W1
Ma, W1
Zhan, Y1
Dai, B1
Ge, S1
Hu, T1
Ta, W1
Lu, S1
He, L1
Fu, X1
Xie, C1
de Barros, CM1
Almeida, CAF1
Pereira, B1
Costa, KCM1
Pinheiro, FA1
Maia, LDB1
Trindade, CM1
Garcia, RCT1
Torres, LH1
Diwan, S1
Boralli, VB1
Nicolò, M1
Ferro Desideri, L1
Bassetti, M1
Traverso, CE1
Jones, CW1
Woodford, AL1
Platts-Mills, TF1
Hushmandi, K1
Bokaie, S1
Hashemi, M1
Moghadam, ER1
Raei, M1
Hashemi, F1
Nabavi, SM1
Kim, YS1
Lee, SY1
Yoon, JW1
Kim, D1
Yu, S1
Kim, JS1
Kim, JH1
Achutha, AS1
Pushpa, VL1
Suchitra, S1
Pereda, R2
Rivero, HB2
Rivero, JC2
Pérez, A2
López, LDR2
Mezquia, N2
Venegas, R2
Betancourt, JR2
Domínguez, RE2
Berling, I1
King, JD1
Shepherd, G1
Hoffman, RS1
Alhatali, B1
Lavergne, V1
Roberts, DM1
Gosselin, S1
Wilson, G1
Nolin, TD1
Ghannoum, M1
Goldman, A1
Bomze, D1
Dankner, R1
Hod, H1
Meirson, T1
Boursi, B1
Maor, E1
Alshaeri, HK1
Natto, ZS1
Perišić, O1
Zhang, XL1
Li, ZM1
Ye, JT1
Ye, LL1
Zhang, CX1
Liu, PQ1
Duan, DD1
Shah, RR1
Allam, MF1
Andraous, F1
Lammers, AJJ1
Brohet, RM1
Theunissen, REP1
Koster, C1
Rood, R1
Verhagen, DWM1
Brinkman, K1
Hassing, RJ1
Dofferhoff, A1
El Moussaoui, R1
Hermanides, G1
Ellerbroek, J1
Bokhizzou, N1
Visser, H1
van den Berge, M1
Bax, H1
Postma, DF1
Groeneveld, PHP1
Ishoso, DK1
Otokoye, JO1
Hermans, MP1
Machekano, RN1
Bongo-Pasi Nswe, C1
Mbala-Kingebeni, P1
Madinga, JN1
Mukendi, S1
Kolié, MC1
Nkwembe, EN1
Mbuyi, GM1
Nsio, JM1
Mukeba Tshialala, D1
Tshiasuma Pipo, M1
Ahuka-Mundeke, S1
Muyembe-Tamfum, JJ1
Mofenson, L1
Smith, G1
Mellors, JW1
Mavungu Landu, DJ1
Kayembe, JM1
Zhang, ZR1
Zhang, YN1
Li, XD1
Zhang, HQ1
Xiao, SQ1
Deng, F1
Yuan, ZM1
Ye, HQ1
Zhang, B1
Sah, AK1
Tripathi, G1
Kashyap, A1
Tripathi, A1
Rao, R1
Mishra, PC1
Mallick, K1
Husain, A1
Kashyap, MK1
Kashour, Z1
Garbati, MA1
AlDosary, O1
Tlayjeh, H1
Gerberi, D1
Sohail, MR1
Kashour, T1
Tleyjeh, IM1
Baroutjian, A1
Sanchez, C1
Boneva, D1
McKenney, M1
Elkbuli, A2
Ortega-Peña, M1
González-Cuevas, R1
Junqueira, DR1
Rowe, BH1
Huang, YY1
Zhan, CG1
Luo, HB1
Marciniec, K1
Beberok, A1
Pęcak, P1
Boryczka, S1
Wrześniok, D1
Peters, EJ1
Collard, D1
Van Assen, S1
Beudel, M1
Bomers, MK1
Buijs, J1
De Haan, LR1
De Ruijter, W1
Douma, RA1
Elbers, PW1
Goorhuis, A1
Gritters van den Oever, NC1
Knarren, LG1
Moeniralam, HS1
Mostard, RL1
Quanjel, MJ1
Reidinga, AC1
Renckens, R1
Van Den Bergh, JP1
Vlasveld, IN1
Sikkens, JJ1
Choi, SW1
Shin, JS1
Park, SJ1
Jung, E1
Park, YG1
Kim, SJ1
Lee, JH1
Park, SM1
Moon, SH1
Ban, K1
Go, YY1
Mallhi, TH2
Ahmad, A1
Butt, MH1
Misbah, S1
Khan, YH2
Alotaibi, NH2
Gavriatopoulou, M1
Ntanasis-Stathopoulos, I1
Korompoki, E1
Fotiou, D1
Migkou, M1
Tzanninis, IG1
Psaltopoulou, T1
Kastritis, E1
Terpos, E1
Dimopoulos, MA1
Zhong, Q1
Peng, J1
Niburski, K1
Niburski, O1
Pimentel, J1
Andersson, N1
Cohen, IV1
Makunts, T1
Moumedjian, T1
Issa, MA1
Abagyan, R1
Murray, K1
Quinn, S1
Turk, M1
O'Rourke, A1
Molloy, E1
O'Neill, L1
Mongey, AB1
Fearon, U1
Veale, DJ1
Punyaratabandhu, P1
Chirachanakul, P1
Cai, T2
Lin, J1
Xiong, Z2
Atakla, HG3
Noudohounsi, MMUD3
Sacca, H2
Tassiou, NRA1
Noudohounsi, WC1
Houinato, DS3
Varshneya, M1
Irurzun-Arana, I1
Campana, C1
Dariolli, R1
Gutierrez, A1
Pullinger, TK1
Sobie, EA1
Berlivet, L1
Löwy, I1
Kumar, M1
Madan, J1
Sodhi, RK1
Singh, SB1
Katyal, A1
Bakadia, BM1
He, F1
Souho, T1
Lamboni, L1
Ullah, MW1
Boni, BO1
Ahmed, AAQ1
Mukole, BM1
Yang, G1
Waffo Tchounga, CA1
Sacre, PY1
Ciza, P1
Ngono, R1
Ziemons, E1
Hubert, P1
Marini, RD1
Mishra, SK1
Tripathi, T1
Uzun, T1
Toptaş, O1
Aydın Türkoğlu, Ş1
Alkasir, A1
Lippmann, S1
Alsharif, MH1
Alsharif, YH1
Albreem, MA1
Jahid, A1
Solyman, AAA1
Yahya, K1
Alomari, OA1
Hossain, MS1
Liu, P1
Yin, M1
Pan, P1
Bouaré, F1
Laghmari, M1
Etouche, FN1
Arjdal, B1
Saidi, I1
Hajhouji, F1
Ghannane, H1
Amro, L1
Tassi, N1
Benali, SA1
Rendic, S1
Guengerich, FP1
Ambrosino, I1
Barbagelata, E1
Corbi, G1
Ciarambino, T1
Politi, C1
Moretti, AM1
Miller-Handley, H1
Luckett, K1
Govil, A1
Laplana, M1
Yuguero, O1
Fibla, J2
Nadeem, U1
Raafey, M1
Kim, G1
Treger, J1
Pytel, P1
N Husain, A1
Schulte, JJ1
Bilgin, ZD1
Evcil, I1
Yazgi, D1
Binay, G1
Okuyucu Genc, C1
Gulsen, B1
Huseynova, A1
Ozdemir, AZ1
Ozmen, E1
Usta, Y1
Ustun, S1
Caglar Andac, S1
Trivedi, N1
Verma, A1
Kumar, D1
Nodarse, H1
Matangila, JR1
Nyembu, RK1
Telo, GM1
Ngoy, CD1
Sakobo, TM1
Massolo, JM1
Muyembe, BM1
Mvwala, RK1
Ilunga, CK1
Limbole, EB1
Ntalaja, JM1
Kongo, RM1
Zequn, Z1
Yujia, W1
Dingding, Q1
Jiangfang, L1
Hussein, MIH1
Albashir, AAD1
Elawad, OAMA1
Homeida, A1
Gomes, CP1
Fernandes, DE1
Casimiro, F1
da Mata, GF1
Passos, MT1
Varela, P1
Mastroianni-Kirsztajn, G1
Pesquero, JB1
Won, JH1
Lee, H1
Becker, ML1
Snijders, D1
van Gemeren, CW1
Kingma, HJ1
van Lelyveld, SFL1
Giezen, TJ1
Niwas, R1
S, AS1
Garg, MK1
Nag, VL1
Bhatia, PK1
Dutt, N1
Chauhan, N1
Charan, J1
Asfahan, S1
Sharma, P1
Bhardwaj, P1
Banerjee, M1
Garg, P1
Sureka, B1
Bohra, GK1
Gopalakrishnan, M1
Misra, S1
Yadav, AK1
Wen, S1
Yu, L1
Noudohounsi, ACWH1
Barry, LF1
Legba, LD1
Souare, IS1
Kaba, F1
Kheirabadi, D1
Haddad, F1
Mousavi-Roknabadi, RS1
Rezaeisadrabadi, M1
Dehghan, H1
Fazlzadeh, A1
Ortonobes Roig, S1
Soler-Blanco, N1
Torrente Jiménez, I1
Van den Eynde Otero, E1
Moreno-Ariño, M1
Gómez-Valent, M1
Badraoui, R1
Adnan, M1
Bardakci, F1
Alreshidi, MM1
Habler, K1
Brügel, M1
Teupser, D1
Liebchen, U1
Scharf, C1
Schönermarck, U1
Vogeser, M1
Paal, M1
Ehrlich, H1
Salami, AY1
Houinato, AG1
Barry, MC1
Othon, GC1
Adjadi, AA1
Raj, CTD1
Kandaswamy, DK1
Danduga, RCSR1
Rajasabapathy, R1
James, RA1
Bignardi, PR1
Vengrus, CS1
Aquino, BM1
Cerci Neto, A1
Cai, L1
Guo, X1
Ying, P1
Hong, L1
Yi, G1
Fu, M1
Mainoli, B1
Machado, T1
Duarte, GS1
Prada, L1
Gonçalves, N1
Ferreira, JJ1
Costa, J1
Shang, C1
Zhuang, X1
Ge, C1
Tian, M1
Jin, N1
Vivanco-Hidalgo, RM1
Molina, I1
Martinez, E1
Roman-Viñas, R1
Sánchez-Montalvá, A1
Pontes, C1
Velasco Muñoz, C1
Szendrey, M1
Kumar, J1
Jain, S2
Meena, J1
Yadav, A1
Galan, LEB1
Santos, NMD1
Asato, MS1
Araújo, JV1
de Lima Moreira, A1
Araújo, AMM1
Paiva, ADP1
Portella, DGS1
Marques, FSS1
Silva, GMA1
de Sousa Resende, J1
Tizolim, MR1
Santos, PL1
Buttenbender, SF1
de Andrade, SB1
Carbonell, RCC1
Da Rocha, JG1
de Souza, RGS1
da Fonseca, AJ1
Altulea, D1
Maassen, S1
Baranov, MV1
van den Bogaart, G1
Minkove, SJ1
Cooper, D1
Couse, Z1
Eichacker, PQ1
Torabi-Parizi, P1
Bokharee, N1
Khokhar, A1
Rasheed, M1
Bhat, EA1
Khan, J1
Sajjad, N1
Ali, A1
Aldakeel, FM1
Mateen, A1
Alqahtani, MS1
Syed, R1
Ferry, T1
Amiet, V1
Natterer, J1
Perez, MH1
Pfister, R1
Colombier, S1
Longchamp, D1
Joshi, G1
Thakur, S1
Poduri, R1
To, KKW1
Lam, H1
Chan, JF1
Lee, ACY1
Cai, J1
Chan, CC1
Yeung, ML1
Zhang, AJ1
Chu, AWH1
Maestro, S1
Córdoba, KM1
Olague, C1
Argemi, J1
Ávila, MA1
González-Aseguinolaza, G1
Smerdou, C1
Fontanellas, A1
Diaz-Arocutipa, C1
Brañez-Condorena, A1
Ogah, OS1
Umuerri, EM1
Adebiyi, A1
Orimolade, OA1
Sani, MU1
Ojji, DB1
Mbakwem, AC1
Stewart, S1
Sliwa, K1
Schicchi, A1
Axfors, C1
Schmitt, AM1
Janiaud, P1
Van't Hooft, J1
Abd-Elsalam, S1
Abdo, EF1
Abella, BS1
Amaravadi, RK1
Angus, DC1
Arabi, YM1
Azhar, S1
Baden, LR1
Baker, AW1
Belkhir, L1
Benfield, T1
Berrevoets, MAH1
Chen, TC1
Chung, WS1
Cohen, YZ1
Cowan, LN1
Dalgard, O1
de Almeida E Val, FF1
de Lacerda, MVG1
de Melo, GC1
Derde, L1
Dubee, V1
Elfakir, A1
Gordon, AC1
Hernandez-Cardenas, CM1
Hills, T1
Huang, YW1
Igau, B1
Jin, R1
Jurado-Camacho, F1
Khan, KS1
Kremsner, PG1
Kreuels, B1
Kuo, CY1
Le, T1
Lin, WP1
Lin, TH1
Lyngbakken, MN1
McArthur, C1
McVerry, BJ1
Meza-Meneses, P1
Morpeth, SC1
Mourad, A1
Mulligan, MJ1
Murthy, S1
Naggie, S1
Narayanasamy, S1
Nichol, A1
Novack, LA1
O'Brien, SM1
Okeke, NL1
Perez, L1
Perrin, L1
Remigio-Luna, A1
Rivera-Martinez, NE1
Rockhold, FW1
Rodriguez-Llamazares, S1
Rolfe, R1
Rosa, R1
Røsjø, H1
Seto, TB1
Shahzad, M1
Soliman, S1
Stout, JE1
Thirion-Romero, I1
Troxel, AB1
Tseng, TY1
Turner, NA1
Ulrich, RJ1
Walsh, SR1
Webb, SA1
Velinova, M1
Wong, HL1
Wrenn, R1
Zampieri, FG1
Moher, D1
Goodman, SN1
Ioannidis, JPA1
Hemkens, LG1
Qiu, R1
Xiao, Y1
Weng, Y1
Gong, H1
Panovska-Stavridis, I1
Ridova, N1
Stojanoska, T1
Demiri, I1
Stevanovic, M1
Stojanovska, S1
Ristevska, T1
Dimkovski, A1
Filipce, V1
Dimovski, A1
Grozdanova, A1
Sirijatuphat, R1
Suputtamongkol, Y1
Angkasekwinai, N1
Horthongkham, N1
Chayakulkeeree, M1
Rattanaumpawan, P1
Koomanachai, P1
Assanasen, S1
Rongrungruang, Y1
Chierakul, N1
Ratanarat, R1
Jitmuang, A1
Wangchinda, W1
Kantakamalakul, W1
Réa-Neto, Á1
Bernardelli, RS1
Câmara, BMD1
Reese, FB1
Queiroga, MVO1
Oliveira, MC1
Li, MX1
Lu, GD1
Shen, HM1
Zhou, J1
Große, M1
Ruetalo, N1
Layer, M1
Hu, D1
Businger, R1
Rheber, S1
Setz, C1
Rauch, P1
Auth, J1
Fröba, M1
Brysch, E1
Schindler, M1
Schubert, U1
Anedda, L1
Bianchini, L1
Cuzzolin, L1
Finco, G1
Fanos, V1
Marcialis, MA1
Potschka, H1
Chandra, PP1
Tripathi, M1
Vohora, D1
Adetuyi, BO1
Olajide, PA1
Awoyelu, EH1
Adetuyi, OA1
Adebisi, OA1
Oloke, JK1
Bu, Y1
Jiang, P1
Lun, B1
Chen, C1
Syafiandini, AF1
Song, M1
Trivedi, A1
Ahmad, R1
Siddiqui, S1
Misra, A1
Khan, MA1
Srivastava, A1
Ahamad, T1
Khan, MF1
Siddiqi, Z1
Afrin, G1
Upadhyay, S1
Husain, I1
Ahmad, B1
Mehrotra, S1
Kant, S1
Prabhakara, C1
Godbole, R1
Sil, P1
Jahnavi, S1
Gulzar, SE1
van Zanten, TS1
Sheth, D1
Subhash, N1
Chandra, A1
Shivaraj, A1
Panikulam, P1
U, I1
Nuthakki, VK1
Puthiyapurayil, TP1
Ahmed, R1
Najar, AH1
Lingamallu, SM1
Mahajan, B1
Vemula, P1
Bharate, SB1
Singh, PP1
Vishwakarma, R1
Guha, A1
Sundaramurthy, V1
Mayor, S1
Ding, J1
Feng, Y1
Bao, Y1
Zhou, Z1
da Rocha, JEB1
Othman, H1
Tiemessen, CT1
Botha, G1
Ramsay, M1
Masimirembwa, C1
Adebamowo, C1
Choudhury, A1
Brandenburg, JT1
Matshaba, M1
Simo, G1
Gamo, FJ1
Hazelhurst, S1
Saheb Sharif-Askari, F1
Saheb Sharif-Askari, N1
Goel, S1
Hafezi, S1
Assiri, R1
Al-Muhsen, S1
Hamid, Q1
Halwani, R1
Raman, R1
Patel, KJ1
Ranjan, K1
Ye, H1
Hu, Y1
Zheng, N1
Fu, L1
Beck-Friis, J1
Leach, S1
Omerovic, E1
Zeijlon, R1
Gisslen, M1
Yilmaz, A1

Clinical Trials (72)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols[NCT05862883]Phase 2301 participants (Actual)Interventional2021-06-01Completed
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194]Phase 31,323 participants (Actual)Interventional2021-01-01Active, not recruiting
Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409]231 participants (Actual)Interventional2020-04-24Completed
An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults[NCT05808231]100 participants (Anticipated)Interventional2021-04-26Recruiting
Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19[NCT04372628]Phase 2452 participants (Actual)Interventional2020-06-01Completed
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial[NCT04339816]Phase 33 participants (Actual)Interventional2020-05-13Terminated (stopped due to Steering Committee decision in accordance with stopping rule 1: Emergence of new data)
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial[NCT04359095]Phase 2/Phase 3650 participants (Actual)Interventional2020-08-18Completed
Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)[NCT04627467]Phase 23,217 participants (Actual)Interventional2020-03-28Completed
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349]Early Phase 1214 participants (Anticipated)Interventional2021-02-01Enrolling by invitation
Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial[NCT04596839]Phase 260 participants (Actual)Interventional2020-09-04Completed
Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia[NCT04420260]152 participants (Actual)Interventional2021-03-18Completed
A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam[NCT04328493]Phase 210 participants (Actual)Interventional2020-04-07Completed
Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections.[NCT04365725]84 participants (Actual)Observational2020-05-05Completed
An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients With Mild Pneumonia - An Open-label Randomized Controlled Study -[NCT04600999]Phase 314 participants (Actual)Interventional2020-10-07Completed
PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037]Phase 239 participants (Actual)Interventional2020-04-07Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.)
Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19: A Descriptive, Longitudinal, Pragmatic Cohort Study[NCT04380870]500 participants (Anticipated)Observational2020-05-11Recruiting
A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization[NCT04365582]Phase 30 participants (Actual)Interventional2020-05-07Withdrawn (stopped due to The PI decided.)
Impact of Colchicine in Hospitalized Colombian Patients With COVID-19[NCT04539873]Phase 3128 participants (Actual)Interventional2021-04-30Terminated (stopped due to non-inclusion of patients in the study effectively)
Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19[NCT04349592]456 participants (Actual)Interventional2020-04-14Completed
Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study[NCT04463264]Phase 2/Phase 3135 participants (Anticipated)Interventional2020-06-26Recruiting
Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial[NCT04345289]Phase 3147 participants (Actual)Interventional2020-05-01Terminated (stopped due to DSMB advise due to high probability of futility)
The Role of the Bacillus Calmette-Guérin Vaccine (BCG) in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) Vaccines[NCT05507671]Phase 3556 participants (Anticipated)Interventional2021-05-27Active, not recruiting
A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting[NCT04370782]Phase 418 participants (Actual)Interventional2020-04-28Completed
Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh[NCT04402203]Phase 2/Phase 350 participants (Anticipated)Interventional2020-05-31Recruiting
Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study)[NCT04400019]Phase 2/Phase 31,930 participants (Anticipated)Interventional2020-09-30Not yet recruiting
Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416]Phase 3204 participants (Anticipated)Interventional2020-06-02Active, not recruiting
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection[NCT04334512]Phase 2600 participants (Anticipated)Interventional2020-06-22Recruiting
Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment[NCT04334967]Phase 413 participants (Actual)Interventional2020-03-30Suspended (stopped due to suspected unfavorable risk/benefit assessment)
Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study[NCT04326725]80 participants (Anticipated)Observational2020-03-20Active, not recruiting
A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics[NCT04353271]Phase 2/Phase 33 participants (Actual)Interventional2020-04-17Terminated (stopped due to FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias)
Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial[NCT04491994]Phase 3540 participants (Actual)Interventional2020-04-10Completed
Efficacy of Chloroquine Phosphate Prophylactic Use in First-line Health Personnel Exposed to COVID-19 Patients[NCT04443270]Phase 1200 participants (Anticipated)Interventional2020-07-27Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection[NCT04335084]Phase 2600 participants (Anticipated)Interventional2020-06-22Recruiting
"Evaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament ACAR en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômes"[NCT04501965]Phase 2231 participants (Actual)Interventional2020-06-01Enrolling by invitation
Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope[NCT04361318]Phase 2/Phase 3100 participants (Anticipated)Interventional2020-05-31Not yet recruiting
Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts[NCT04652648]Phase 454 participants (Actual)Interventional2020-05-27Completed
Évaluationefficacité et tolérance d'Une médication à Base de Cosphérunate et d'un phytomédicament Antiviral Par Voie Orale en Comparaison Avec un Traitement à Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications[NCT04502342]Phase 230 participants (Actual)Interventional2020-06-01Enrolling by invitation
Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial[NCT04387760]Phase 2150 participants (Actual)Interventional2020-08-11Completed
Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine in Colombia[NCT04654416]301 participants (Actual)Observational2020-03-20Completed
Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial[NCT04356534]40 participants (Actual)Interventional2020-04-19Completed
A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh[NCT04434144]116 participants (Actual)Observational [Patient Registry]2020-05-02Completed
Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial[NCT04354441]Phase 20 participants (Actual)Interventional2020-05-31Withdrawn (stopped due to Not started)
Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study[NCT04341441]Phase 3624 participants (Actual)Interventional2020-04-07Terminated (stopped due to Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.)
Observational Study of COVID-19 Treatment Efficacy[NCT04369989]250 participants (Actual)Observational2020-04-14Terminated (stopped due to Review of data revealed poor correlation with hypothesis and data quality challenges.)
Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19)[NCT04361526]40 participants (Anticipated)Interventional2020-04-17Recruiting
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers: A Randomized-Controlled Trial[NCT04438837]582 participants (Anticipated)Interventional2020-07-31Not yet recruiting
Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial[NCT04344951]Phase 229 participants (Actual)Interventional2020-04-06Terminated (stopped due to No clinical efficacy against SARS-CoV-2 recorded)
MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19[NCT04632719]200 participants (Anticipated)Interventional2020-11-08Recruiting
Clinical Course of COVID-19 in Patients With Rheumatoid Arthritis Treated With or Without Hydroxychloroquine: a Case-control Study[NCT04471649]80 participants (Anticipated)Observational2020-06-15Recruiting
A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment[NCT04384380]33 participants (Actual)Interventional2020-04-01Completed
Health-related Quality of Life (HRQOL) and Physical Performance in Individuals After COVID-19 Induced Hospitalisation and the Impact of a Standard Care Follow-up Program: a Longitudinal Observational Cohort Study[NCT04375709]60 participants (Anticipated)Observational2020-03-15Recruiting
Viral Kinetics of SARS-CoV-2 in Patients in the Intensive Care Unit Undergoing Dental Procedures[NCT05311410]60 participants (Anticipated)Interventional2021-09-20Recruiting
Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment[NCT04981379]Phase 31,120 participants (Actual)Interventional2020-11-16Completed
Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist[NCT04594356]120 participants (Actual)Observational2020-11-19Completed
Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic[NCT04540926]Phase 1/Phase 2200 participants (Anticipated)Interventional2020-09-30Not yet recruiting
Nutritional Habits, Does it Affect Coronavirus Disease 2019 (COVID-19) Infection Outcome? An Egyptian Experience[NCT04447144]200 participants (Anticipated)Observational2020-06-01Recruiting
Evaluation of Independent Clinical- Laboratory Predictors of Clinical Outcomes in Hospitalized Positive SARS-CoV2 Patients (Outcomes SARS-CoV2)[NCT05162534]1,800 participants (Actual)Observational2020-05-29Completed
Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in Covid 19 Patients With and Without Bacterial Sepsis[NCT04920851]23 participants (Anticipated)Observational2021-06-10Recruiting
Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial[NCT04397328]Phase 3336 participants (Anticipated)Interventional2020-05-19Not yet recruiting
Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact[NCT04358614]Phase 2/Phase 312 participants (Actual)Interventional2020-03-16Completed
The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.[NCT04480593]Phase 2/Phase 3120 participants (Actual)Interventional2020-06-02Completed
Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial[NCT04392713]100 participants (Anticipated)Interventional2020-04-15Recruiting
Ivermectin Will be Used as an Outpatient Treatment Option for COVID-19 Patients.[NCT05045937]1,000 participants (Anticipated)Observational [Patient Registry]2022-05-01Recruiting
Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled[NCT04529525]Phase 2/Phase 3501 participants (Actual)Interventional2020-08-19Completed
Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients[NCT04472585]Phase 1/Phase 2180 participants (Anticipated)Interventional2020-11-14Recruiting
Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Therapeutic Safety of Ivermectin Versus Placebo Associated With Standard of Care Treatment in the Early Phase of Coronavirus Infection (COVID19).[NCT04836299]Phase 290 participants (Anticipated)Interventional2021-05-08Not yet recruiting
Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study[NCT04375202]Phase 2227 participants (Actual)Interventional2020-04-18Terminated (stopped due to Insufficient rate of patient accrual and newly available scientific evidence)
Evaluation of Awake Prone Positioning Effectiveness in Moderate to Severe COVID-19[NCT05083130]93 participants (Actual)Interventional2022-03-08Completed
Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial[NCT04323527]Phase 2278 participants (Actual)Interventional2020-03-23Completed
Randomized Controlled Trial on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow[NCT05062681]Phase 460 participants (Anticipated)Interventional2021-09-15Recruiting
Remdesivir Versus Remdesivir- Ivermectin Combination Therapy in Severe and Critically Ill Covid-19[NCT04944082]Phase 460 participants (Anticipated)Interventional2021-07-01Not yet recruiting
Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19[NCT04420247]Phase 3142 participants (Actual)Interventional2020-04-16Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Count of Participants Who Died

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group0
Treatment Arm - Placebo Group0
Treatment Arm - Ivermectin Only Group0
Treatment Arm - Fluvoxamine Only Group0
Treatment Arm - Metformin and Fluvoxamine Group0
Treatment Arm - Metformin and Ivermectin Group1

Count of Participants With ED Visit, Hospitalization or Death

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group27
Treatment Arm - Placebo Group48
Treatment Arm - Ivermectin Only Group16
Treatment Arm - Fluvoxamine Only Group15
Treatment Arm - Metformin and Fluvoxamine Group18
Treatment Arm - Metformin and Ivermectin Group23

Count of Participants With Hospitalization or Death

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group8
Treatment Arm - Placebo Group18
Treatment Arm - Ivermectin Only Group5
Treatment Arm - Fluvoxamine Only Group5
Treatment Arm - Metformin and Fluvoxamine Group6
Treatment Arm - Metformin and Ivermectin Group4

Count of Participants With Hypoxia Only

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group147
Treatment Arm - Placebo Group158
Treatment Arm - Ivermectin Only Group88
Treatment Arm - Fluvoxamine Only Group73
Treatment Arm - Metformin and Fluvoxamine Group71
Treatment Arm - Metformin and Ivermectin Group96

Fever-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days without fever from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir16
Placebo Control Group17

Hospital-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days outside the hospital from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir17
Placebo Control Group17

ICU-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days outside the ICU from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir17
Placebo Control Group17

Oxygen-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of Days without oxygen Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir17
Placebo Control Group17

Time to Hospitalization Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days from enrollment to hospitalization (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir6
Placebo Control Group7

Time to Symptom Resolution: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days from enrollment to resolution of COVID-19 symptoms (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir11
Placebo Control Group11

Vasopressor-free Days Through Study Day 29 (Group 2 and Placebo Control Group)

Number of vasopressor-free days through Study Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir17
Placebo Control Group17

Ventilator-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days without ventilator use from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir17
Placebo Control Group17

Sub Study 1 - Rate of Negative Tests at End of Treatment for COVID-19 Positive PCR Patients in Self-quarantine

Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)4
Sub Study 1 Group 2 (Placebo)0

Sub Study 1 - Rate of Negative Tests at End of Treatment for COVID-19 Positive PCR Patients in Self-quarantine

Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)6
Sub Study 1 Group 2 (Placebo)0

Sub Study 1 - Secondary Infection of Co-inhabitants of COVID-19 Positive PCR Patients in Self-quarantine

Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)0
Sub Study 1 Group 2 (Placebo)0

Sub Study 2:Health Care Workers:Rate of Hospitalization

if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.

InterventionParticipants (Count of Participants)
Sub Study 2 Group 1 (HCQ)0
Sub Study 2 Group 2 (Placebo)0

Sub Study 2:Number of Health Care Workers Testing Positive at 2 Months

Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.

InterventionParticipants (Count of Participants)
Sub Study 2 Group 1 (HCQ)0
Sub Study 2 Group 2 (Placebo)0

Substudy 1 - Number of COVID-19+ PCR Patients in Self-quarantine Who Are Hospitalized

Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)0
Sub Study 1 Group 2 (Placebo)0

Sub Study 2:Health Care Workers: Assessment of Any Medical Events That Occur During the ~60 Day Active Period

Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.

,
InterventionParticipants (Count of Participants)
moderate adverse eventsminor adverse events
Sub Study 2 Group 1 (HCQ)21
Sub Study 2 Group 2 (Placebo)00

Number of Participants Who Are Hospitalized for Covid 19 Infection

Number of subjects in each arm who are hospitalized for Covid 19 infection (NCT04353271)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment0
Control0

Number of Participants Who Are Virus Free

Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs (NCT04353271)
Timeframe: 7 days after initiation of trial

Interventionparticipants (Number)
Treatment0
Control0

Number of Participants Who Die Secondary to Covid 19 Infection

Number of subjects in each arm who die secondary to Covid-19 infection (NCT04353271)
Timeframe: 70 Days (10 weeks)

InterventionParticipants (Count of Participants)
Treatment0
Control0

Number of Participants Who Discontinue or Withdraw Medication Use for Any Reason

Number of subjects in each arm who discontinue or withdraw medication use for any reason (NCT04353271)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment0
Control1

Number of Participants Who Have Confirmed Covid 19 Infection

Number of subjects in each arm who have confirmed Covid-19 infection (NCT04353271)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment1
Control2

Number of Participants With Progression

After start of treatment, development of fever > 101 F for > 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic lab parameters (ALC < 1000 or raised CRP) or appearance of infiltrates on CXR during course of treatment was labeled as progression irrespective of PCR status (NCT04491994)
Timeframe: 5 days

InterventionParticipants (Count of Participants)
Standard of Care (SOC)5
Intervention Group11

Assess the Impact of Chronic Weight-based Dosing of HCQ for COVID-19 Prevention.

Compare the rates of SARS-CoV 2 infections (number of events of symptomatic patients with a positive COVID-19 test) in the non-randomized comparator arm to the randomized hydroxychloroquine and placebo arms to assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention via weekly questionnaire and/or blood samples. This analysis includes all randomized and non-randomized groups in the study. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo1
Non-Randomized Active Comparator0

Compare the Seroprevalence of SARS-CoV 2 IgM and/or IgG Positive Samples at Study Entry and Study Conclusion in All Participants Receiving HCQ Compared to Those Receiving Placebo.

Measurement of the seroprevalence of SARS-CoV 2 IgM and/or IgG positive samples in all arms of the study, randomized and non-randomized (Study Drug - Daily Dose, Study Drug - Weekly Dose, Placebo, and Non-Randomized Active Comparator). (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo2
Non-Randomized Active Comparator0

Comparison of the Emergence of Clinical Symptoms or COVID-19 Diagnosis in Participants Presenting Asymptomatically at Study Entry But Identified as Seropositive by Serology at Entry Between the Randomized Treatment Arms and Comparator Arm.

Measurement of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm and via weekly questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose0
Placebo0
Non-Randomized Active Comparator0

Comparison of the Rate of SARS-CoV 2 Infections as Measured by IgM/IgG Seroconversion in Study Participants Receiving Randomized HCQ Versus Placebo.

Measurement of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo via blood samples in the randomized arms of the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo2

Determine the Effect of Hydroxychloroquine Dose in the Prevention of COVID-19 Viremia and Disease.

Compare the rates of SARS-CoV 2 symptomatic infections (number of events with both symptoms and positive test for COVID-19) between the randomized hydroxychloroquine treatment arms and the placebo control arm to determine the effect of HCQ dose in the prevention of COVID-19 viremia and disease. This analysis only includes only the randomized arms in the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo1

Examine the Correlation Between HCQ Drug Levels and Development of COVID-19 Symptoms or Positive COVID-19 Test Results.

Examination of the correlation between HCQ drug levels and development of COVID-19 clinical symptoms and/or positive COVID-19 test results via weekly subject questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks

InterventionCorrelation coefficient (Number)
Study Drug - Daily DoseNA
Study Drug - Weekly DoseNA
PlaceboNA
Non-Randomized Active ComparatorNA

Identify Immunologic, Serological and Inflammatory Markers Associated With Acquisition and Response to COVID-19 in Both HCQ and Placebo Participants Developing Laboratory or Clinical Confirmed Disease.

Identification of immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease via study visits, weekly questionnaire, and blood samples. (NCT04341441)
Timeframe: 8 weeks

InterventionInflammatory markers (Number)
Study Drug - Daily DoseNA
Study Drug - Weekly DoseNA
PlaceboNA
Non-Randomized Active ComparatorNA

To Determine if the Use of Hydroxychloroquine as Preventive Therapy Decreases the Rate of Acquisition of SARS-CoV 2 Infections With Clinical COVID-19 Disease in Study Participants for Each Randomized Treatment Arm as Compared to Placebo.

The rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease (number of events) in study participants for each randomized hydroxychloroquine treatment arm was compared to the placebo treatment arm. This included both symptomatic and asymptomatic patients. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo1
Non-Randomized Active Comparator0

To Examine Other Clinical Factors Contributing to the Risk of SARS-CoV 2 Infection in Healthcare Workers and First Responders.

Examination of other clinical factors contributing to the risk of SARS-CoV 2 infection including demographics, work type and location, positive COVID-19 partners, possible exposures and clinical symptoms via study visits and weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks

InterventionClinical factors (Number)
Study Drug - Daily DoseNA
Study Drug - Weekly DoseNA
PlaceboNA
Non-Randomized Active ComparatorNA

To Examine the Level of Care Needed by Participants in Each Arm Developing COVID19 as Measured as Requiring Emergency Room Visit, Hospitalization or Able to Stay Home Without Hospital Care.

Review of the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose0
Study Drug - Weekly Dose0
Placebo0
Non-Randomized Active Comparator0

Determine the Safety and Tolerability of HCQ Dosing for Preventive Strategy Against COVID-19 as Measured by Adverse Events and Serious Adverse Events.

Measurement of the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events reported via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks

,,,
InterventionNumber of adverse events. (Number)
Adverse events (only Level 1 and 2) observed in the study.Serious adverse events (Level 3 or 4).
Non-Randomized Active Comparator20
Placebo1880
Study Drug - Daily Dose2060
Study Drug - Weekly Dose1930

Reviews

160 reviews available for chloroquine and 2019 Novel Coronavirus Disease

ArticleYear
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Journal of medicinal chemistry, 2020, 11-25, Volume: 63, Issue:22

    Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs,

2020
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
    Medicinal research reviews, 2021, Volume: 41, Issue:1

    Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans

2021
Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
    Reumatologia clinica, 2021, Volume: 17, Issue:8

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Combined

2021
Current treatment strategies for COVID‑19 (Review).
    Molecular medicine reports, 2021, Volume: 24, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Chloroquine; COVID-19; C

2021
Possible mechanistic insights into iron homeostasis role of the action of 4-aminoquinolines (chloroquine/hydroxychloroquine) on COVID-19 (SARS-CoV-2) infection.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:23

    Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Homeostasis; Humans; Hydroxychlo

2021
Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection.
    Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2022, Volume: 71

    Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Iverme

2022
COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19.
    Current medicinal chemistry, 2022, Volume: 29, Issue:20

    Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Humans; H

2022
How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
    Internal medicine journal, 2023, Volume: 53, Issue:3

    Topics: Antirheumatic Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Friends; Humans; Hydroxychloro

2023
Hydroxychloroquine for Non-Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Arquivos brasileiros de cardiologia, 2023, Volume: 120, Issue:4

    Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Randomized Controlled Tr

2023
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.
    European journal of clinical pharmacology, 2023, Volume: 79, Issue:6

    Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; Dexamethasone; Drug Repositioning; Humans; Hy

2023
A study on the effect of natural products against the transmission of B.1.1.529 Omicron.
    Virology journal, 2023, 08-25, Volume: 20, Issue:1

    Topics: Angiotensin-Converting Enzyme 2; Biological Products; Chloroquine; COVID-19; COVID-19 Drug Treatment

2023
Clinical trial analysis of 2019-nCoV therapy registered in China.
    Journal of medical virology, 2020, Volume: 92, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Cli

2020
Of chloroquine and COVID-19.
    Antiviral research, 2020, Volume: 177

    Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infecti

2020
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019.
    World journal of pediatrics : WJP, 2020, Volume: 16, Issue:3

    Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; China; Chloroquine; Coronavirus

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Trial of Chloroquines in the Treatment of COVID-19 and Its Research Progress in Forensic Toxicology.
    Fa yi xue za zhi, 2020, Volume: 36, Issue:2

    Topics: Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fore

2020
Controversial treatments: An updated understanding of the coronavirus disease 2019.
    Journal of medical virology, 2020, Volume: 92, Issue:9

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment;

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
Emerging prophylaxis strategies against COVID-19.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Mar-30, Volume: 90, Issue:1

    Topics: Antiviral Agents; Betacoronavirus; Chemoprevention; Chloroquine; Clinical Trials as Topic; Coronavir

2020
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
    Pharmacotherapy, 2020, Volume: 40, Issue:5

    Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antivi

2020
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, Apr-27, Volume: 192, Issue:17

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe

2020
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, Apr-27, Volume: 192, Issue:17

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe

2020
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, Apr-27, Volume: 192, Issue:17

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe

2020
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, Apr-27, Volume: 192, Issue:17

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe

2020
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infect

2020
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
    International journal of rheumatic diseases, 2020, Volume: 23, Issue:5

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19

2020
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
    JAMA, 2020, May-12, Volume: 323, Issue:18

    Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists;

2020
COVID-19 and neuromuscular disorders.
    Neurology, 2020, 06-02, Volume: 94, Issue:22

    Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Delivery of Heal

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1
    Annales de cardiologie et d'angeiologie, 2020, Volume: 69, Issue:3

    Topics: Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Cardiomyopathies; Cardiovascular Dis

2020
Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.
    Clinical pharmacokinetics, 2020, Volume: 59, Issue:6

    Topics: Adult; Antimalarials; Child; Chloroquine; Coronavirus Infections; COVID-19; Drug Repositioning; Huma

2020
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
    Journal of autoimmunity, 2020, Volume: 111

    Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Chloroqu

2020
Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings.
    The American journal of tropical medicine and hygiene, 2020, Volume: 102, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Continuous Positive Airway Pressure;

2020
COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
    Pediatric rheumatology online journal, 2020, Apr-22, Volume: 18, Issue:1

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Juvenile; Beta

2020
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020, Volume: 39, Issue:7

    Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Me

2020
COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.
    Journal of clinical epidemiology, 2020, Volume: 123

    Topics: Biomedical Research; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Obse

2020
Current status of potential therapeutic candidates for the COVID-19 crisis.
    Brain, behavior, and immunity, 2020, Volume: 87

    Topics: Adrenal Cortex Hormones; Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents, Non-Steroidal; A

2020
Treatment of SARS-CoV-2: How far have we reached?
    Drug discoveries & therapeutics, 2020, May-06, Volume: 14, Issue:2

    Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betac

2020
Cardiovascular manifestations and treatment considerations in COVID-19.
    Heart (British Cardiac Society), 2020, Volume: 106, Issue:15

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inh

2020
COVID-19: Therapeutics and Their Toxicities.
    Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2020, Volume: 16, Issue:3

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychl

2020
A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2020, Volume: 27, Issue:6

    Topics: Antimalarials; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID

2020
Medical treatment options for COVID-19.
    European heart journal. Acute cardiovascular care, 2020, Volume: 9, Issue:3

    Topics: Adenosine Monophosphate; Administration, Intravenous; Alanine; Amides; Antibodies, Monoclonal, Human

2020
Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report.
    QJM : monthly journal of the Association of Physicians, 2020, 08-01, Volume: 113, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infectio

2020
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
    European heart journal. Acute cardiovascular care, 2020, Volume: 9, Issue:3

    Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimalarials; Arrhythmias, Cardiac; Betacoronavirus;

2020
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:8

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO

2020
Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19.
    Archivos de la Sociedad Espanola de Oftalmologia, 2020, Volume: 95, Issue:6

    Topics: Antimalarials; Asymptomatic Diseases; Betacoronavirus; Blood Safety; Chloroquine; Contact Lenses; Co

2020
Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2020, Volume: 59, Issue:2

    Topics: Adult; Aged; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections;

2020
A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
    Life sciences, 2020, Aug-01, Volume: 254

    Topics: Aminoquinolines; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavir

2020
Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
    Acta medica portuguesa, 2020, Jul-01, Volume: 33, Issue:7-8

    Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavir

2020
Should coronavirus disease 2019 concern rheumatologists?
    Polish archives of internal medicine, 2020, 08-27, Volume: 130, Issue:7-8

    Topics: Antirheumatic Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans

2020
The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
    Pharmacological research, 2020, Volume: 158

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
    Circulation. Arrhythmia and electrophysiology, 2020, Volume: 13, Issue:6

    Topics: Antimalarials; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-

2020
[Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].
    Medicina, 2020, Volume: 80, Issue:3

    Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Cardiovascular Di

2020
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:2

    Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infecti

2020
[Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)].
    Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control, 2020, Apr-22, Volume: 32, Issue:2

    Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Humans; Pan

2020
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
    Annals of internal medicine, 2020, 08-18, Volume: 173, Issue:4

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
    Journal of the American Heart Association, 2020, 06-16, Volume: 9, Issue:12

    Topics: Betacoronavirus; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; Global Health; Heart

2020
Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020, Volume: 26, Issue:8

    Topics: Adult; Antiviral Agents; Betacoronavirus; Child; Chloroquine; Clinical Trials as Topic; Coronavirus

2020
The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.
    Arquivos brasileiros de cardiologia, 2020, 06-01, Volume: 114, Issue:5

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Animals; Antirheumatic Agents; An

2020
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, 07-06, Volume: 192, Issue:27

    Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
    Clinical rheumatology, 2020, Volume: 39, Issue:8

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO

2020
Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
    Postgraduate medicine, 2020, Volume: 132, Issue:7

    Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 229E, H

2020
A current review of COVID-19 for the cardiovascular specialist.
    American heart journal, 2020, Volume: 226

    Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Biomarkers; Card

2020
Coronavirus Disease 2019: Clinical Review.
    Acta medica portuguesa, 2020, Jul-01, Volume: 33, Issue:7-8

    Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus;

2020
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    In vivo (Athens, Greece), 2020, Volume: 34, Issue:3 Suppl

    Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Beta

2020
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
    Advances in rheumatology (London, England), 2020, 06-09, Volume: 60, Issue:1

    Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine;

2020
Lithium and coronaviral infections. A scoping review.
    F1000Research, 2020, Volume: 9

    Topics: Animals; Betacoronavirus; Cells, Cultured; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Lithium and coronaviral infections. A scoping review.
    F1000Research, 2020, Volume: 9

    Topics: Animals; Betacoronavirus; Cells, Cultured; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Lithium and coronaviral infections. A scoping review.
    F1000Research, 2020, Volume: 9

    Topics: Animals; Betacoronavirus; Cells, Cultured; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Lithium and coronaviral infections. A scoping review.
    F1000Research, 2020, Volume: 9

    Topics: Animals; Betacoronavirus; Cells, Cultured; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
    Virus research, 2020, Volume: 286

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Cor

2020
Treatment of COVID 19-Repurposing drugs commonly used in dermatology.
    Dermatologic therapy, 2020, Volume: 33, Issue:5

    Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dermatology; Drug Repositioning; H

2020
Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19.
    Current drug targets, 2020, Volume: 21, Issue:16

    Topics: Aminoquinolines; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Tr

2020
Dissecting the interaction between COVID-19 and diabetes mellitus.
    Journal of diabetes investigation, 2020, Volume: 11, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID-

2020
Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
    European urology focus, 2020, Sep-15, Volume: 6, Issue:5

    Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral

2020
Chloroquine in controlling biological infections.
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2020, Jun-17, Volume: 48, Issue:285

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Cardiac effects and toxicity of chloroquine: a short update.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:2

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pan

2020
[Drug treatment of coronavirus disease COVID-19: evidence exists?]
    Khirurgiia, 2020, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme In

2020
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
    Biochemical pharmacology, 2020, Volume: 178

    Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral

2020
Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?
    Drug discoveries & therapeutics, 2020, Jul-15, Volume: 14, Issue:3

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cytokines; Drug Delive

2020
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
    Cardiorenal medicine, 2020, Volume: 10, Issue:5

    Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Betacoronavirus; CCR5 Receptor Antagonis

2020
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:3

    Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Autopha

2020
Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
    Expert review of anti-infective therapy, 2020, Volume: 18, Issue:11

    Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Dru

2020
The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
    Current pharmaceutical design, 2020, Volume: 26, Issue:35

    Topics: Autoimmune Diseases; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxy

2020
Is hydroxychloroquine beneficial for COVID-19 patients?
    Cell death & disease, 2020, 07-08, Volume: 11, Issue:7

    Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chlor

2020
Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population.
    Current drug metabolism, 2020, Volume: 21, Issue:7

    Topics: Adult; Aged; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections;

2020
Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.
    JAMA network open, 2020, 07-01, Volume: 3, Issue:7

    Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antimala

2020
SARS-COV-2 in Ophthalmology: Current Evidence and Standards for Clinical Practice.
    Acta medica portuguesa, 2020, Sep-01, Volume: 33, Issue:9

    Topics: Aged; Antiviral Agents; Betacoronavirus; Chloroquine; Conjunctiva; Conjunctivitis, Viral; Coronaviru

2020
Targeting zinc metalloenzymes in coronavirus disease 2019.
    British journal of pharmacology, 2020, Volume: 177, Issue:21

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Enzymes; Hu

2020
Role for antimalarials in the management of COVID-19.
    Current opinion in rheumatology, 2020, Volume: 32, Issue:5

    Topics: Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVI

2020
Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.
    Life sciences, 2020, Sep-15, Volume: 257

    Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Computational Biolo

2020
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.
    Journal of critical care, 2020, Volume: 59

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2020, Volume: 97, Issue:9

    Topics: Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVI

2020
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:3

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic;

2020
Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.
    Vascular, 2021, Volume: 29, Issue:2

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Azithromycin; Cardiovascular Diseases; Chemicall

2021
An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2020, Volume: 144

    Topics: Animals; Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; D

2020
Advances and challenges in the prevention and treatment of COVID-19.
    International journal of medical sciences, 2020, Volume: 17, Issue:12

    Topics: Amides; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Chloroquine; Chlorpromazine; Coro

2020
Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.
    The western journal of emergency medicine, 2020, Jun-03, Volume: 21, Issue:4

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
    Archives of pharmacal research, 2020, Volume: 43, Issue:8

    Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydro

2020
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
    Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Bias; C

2021
Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020, Volume: 18, Issue:8

    Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Doxycycline; Humans; Hydroxychloro

2020
Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 130

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Che

2020
Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19?
    Recent patents on anti-infective drug discovery, 2020, Volume: 15, Issue:2

    Topics: Animals; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pre-Exposure Pr

2020
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.
    American journal of critical care : an official publication, American Association of Critical-Care Nurses, 2020, 11-01, Volume: 29, Issue:6

    Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Heart Diseases; Hospi

2020
Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2.
    The Journal of international medical research, 2020, Volume: 48, Issue:8

    Topics: Adenosine Monophosphate; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents;

2020
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021, Volume: 27, Issue:1

    Topics: Antiviral Agents; Azithromycin; Bayes Theorem; Bias; Chloroquine; COVID-19; COVID-19 Drug Treatment;

2021
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 131

    Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavir

2020
Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis.
    Trends in immunology, 2020, Volume: 41, Issue:10

    Topics: Angiotensin-Converting Enzyme Inhibitors; Autophagy; Azithromycin; Betacoronavirus; Chloroquine; Cor

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2020, Volume: 40, Issue:10

    Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronav

2020
Traditional Chinese Medicine as Potential Therapy for COVID-19.
    The American journal of Chinese medicine, 2020, Volume: 48, Issue:6

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agen

2020
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.
    Pharmacology & therapeutics, 2020, Volume: 216

    Topics: Animals; Antimalarials; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Corona

2020
COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    Pain physician, 2020, Volume: 23, Issue:4S

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
    International ophthalmology, 2021, Volume: 41, Issue:2

    Topics: Antimalarials; Chloroquine; COVID-19; COVID-19 Drug Treatment; Disease Outbreaks; Humans; Hydroxychl

2021
A review of medications used to control and improve the signs and symptoms of COVID-19 patients.
    European journal of pharmacology, 2020, Nov-15, Volume: 887

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19

2020
Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
    Journal of the American Society of Nephrology : JASN, 2020, Volume: 31, Issue:10

    Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychlor

2020
A contemporary look at COVID-19 medications: available and potentially effective drugs.
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:17

    Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacor

2020
Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.
    Acta pharmacologica Sinica, 2020, Volume: 41, Issue:11

    Topics: Antiviral Agents; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
    Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:1

    Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dose-Response Relati

2021
Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.
    Biochemical and biophysical research communications, 2021, 01-29, Volume: 538

    Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Primary Prevention

2021
Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Molecular and cellular biochemistry, 2021, Volume: 476, Issue:2

    Topics: Angiotensin-Converting Enzyme 2; China; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Ser

2021
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis.
    The Journal of antimicrobial chemotherapy, 2021, 01-01, Volume: 76, Issue:1

    Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Hospitalization; Hum

2021
SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
    The American journal of emergency medicine, 2020, Volume: 38, Issue:11

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment;

2020
Familiar Dermatologic Drugs as Therapies for COVID-19.
    Actas dermo-sifiliograficas, 2021, Volume: 112, Issue:2

    Topics: Androgen Antagonists; Antimalarials; Antioxidants; Antiparasitic Agents; Chloroquine; Cinchona; COVI

2021
Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:4

    Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Databases, Factual; Endpoint Deter

2021
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021, Volume: 27, Issue:1

    Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combin

2021
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2020, Volume: 30, Issue:10

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Emerging treatment strategies for COVID-19 infection.
    Clinical and experimental medicine, 2021, Volume: 21, Issue:2

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Tre

2021
Chloroquine and its derivatives in the management of COVID-19: A scoping review
    Biomedica : revista del Instituto Nacional de Salud, 2020, 10-30, Volume: 40, Issue:Supl. 2

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Compassionate Use Trials;

2020
Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients.
    European journal of clinical pharmacology, 2021, Volume: 77, Issue:4

    Topics: Administration, Oral; Adult; Aged; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dose-Response Rel

2021
Decoding the silent walk of COVID-19: Halting its spread using old bullets.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 133

    Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydrox

2021
Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 133

    Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloroquine

2021
One year update on the COVID-19 pandemic: Where are we now?
    Acta tropica, 2021, Volume: 214

    Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as

2021
Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:22

    Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Artificial In

2020
Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.
    Current drug metabolism, 2020, Volume: 21, Issue:14

    Topics: Animals; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme Inhibitors; Cytochr

2020
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
    Advances in chronic kidney disease, 2020, Volume: 27, Issue:5

    Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanize

2020
Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.
    American journal of clinical pathology, 2021, 05-18, Volume: 155, Issue:6

    Topics: Antimalarials; Antiviral Agents; Cardiomyopathies; Chloroquine; COVID-19; COVID-19 Drug Treatment; H

2021
Liquid Chromatographic Methods for COVID-19 Drugs, Hydroxychloroquine and Chloroquine.
    Journal of chromatographic science, 2021, Aug-18, Volume: 59, Issue:8

    Topics: Animals; Antiviral Agents; Chloroquine; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; H

2021
Possible treatment and strategies for COVID-19: review and assessment.
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:23

    Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodie

2020
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    European journal of pharmacology, 2021, Feb-15, Volume: 893

    Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; ERG1 Potassium Chan

2021
Malaria and COVID-19: unmasking their ties.
    Malaria journal, 2020, Dec-23, Volume: 19, Issue:1

    Topics: Age Factors; Angiotensin-Converting Enzyme 2; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans

2020
Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics.
    Frontiers in cellular and infection microbiology, 2020, Volume: 10

    Topics: Acute Kidney Injury; Amantadine; Angiotensin-Converting Enzyme 2; Cathepsin L; Chloroquine; COVID-19

2020
The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.
    International journal of molecular sciences, 2020, Dec-21, Volume: 21, Issue:24

    Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines;

2020
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
    Annals of palliative medicine, 2021, Volume: 10, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azeti

2021
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
    Journal of medical virology, 2021, Volume: 93, Issue:5

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Tre

2021
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
    Archives of microbiology, 2021, Volume: 203, Issue:5

    Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19

2021
Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials.
    Pathogens and global health, 2021, Volume: 115, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Fe

2021
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    The Cochrane database of systematic reviews, 2021, 02-12, Volume: 2

    Topics: Adult; Aged; Antimalarials; Antiviral Agents; Bias; Cause of Death; Chloroquine; COVID-19; COVID-19

2021
Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?
    Saudi medical journal, 2021, Volume: 42, Issue:3

    Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-C

2021
Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:6

    Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Treatm

2021
What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.
    Journal of molecular cell biology, 2021, 07-06, Volume: 13, Issue:3

    Topics: Antiviral Agents; Cell Proliferation; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositio

2021
Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.
    Reviews in medical virology, 2021, Volume: 31, Issue:6

    Topics: Alphapapillomavirus; Antiviral Agents; Chikungunya Fever; Chikungunya virus; Chloroquine; COVID-19;

2021
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
    Expert review of anti-infective therapy, 2021, Volume: 19, Issue:10

    Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanize

2021
SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis - An updated review.
    International immunopharmacology, 2021, Volume: 95

    Topics: Adenosine Monophosphate; Alanine; Animals; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19

2021
Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2021, Volume: 151

    Topics: Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquin

2021
QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Pharmacoepidemiology and drug safety, 2021, Volume: 30, Issue:6

    Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Long QT Sy

2021
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
    Global heart, 2021, 03-15, Volume: 16, Issue:1

    Topics: Acute Coronary Syndrome; Africa; Antimalarials; Arrhythmias, Cardiac; Cardiovascular Diseases; Chlor

2021
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
    Nature communications, 2021, 04-15, Volume: 12, Issue:1

    Topics: Adult; Child; Chloroquine; Combined Modality Therapy; Comorbidity; COVID-19; COVID-19 Drug Treatment

2021
The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis.
    Medicine, 2021, Apr-23, Volume: 100, Issue:16

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Chloro

2021
Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
    Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki), 2021, Apr-23, Volume: 42, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine;

2021
Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.
    International journal of biological sciences, 2021, Volume: 17, Issue:6

    Topics: Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; E

2021
What if COVID-19 affects the child: which weapons and how to use them.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:8

    Topics: Adenosine Monophosphate; Adolescent; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Antico

2021
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
    Epilepsy research, 2021, Volume: 174

    Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanize

2021
Epidemiology and Treatment Options for COVID-19: A Review.
    African journal of reproductive health, 2020, Volume: 24, Issue:s1

    Topics: Antiviral Agents; Chloroquine; Communicable Disease Control; COVID-19; Disease Outbreaks; Humans; Hy

2020
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.
    Biomolecules, 2021, 07-06, Volume: 11, Issue:7

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Chloroquine; COVID-19;

2021

Trials

10 trials available for chloroquine and 2019 Novel Coronavirus Disease

ArticleYear
Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria.
    West African journal of medicine, 2023, 10-31, Volume: 40, Issue:10

    Topics: Adult; Chloroquine; COVID-19; Humans; Hydroxychloroquine; Middle Aged; Nigeria; SARS-CoV-2; Treatmen

2023
Treating COVID-19 with Chloroquine.
    Journal of molecular cell biology, 2020, 05-18, Volume: 12, Issue:4

    Topics: Adult; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Lo

2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
    JAMA network open, 2020, 04-24, Volume: 3, Issue:4

    Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Chloroq

2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
    JAMA network open, 2020, 04-24, Volume: 3, Issue:4

    Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Chloroq

2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
    JAMA network open, 2020, 04-24, Volume: 3, Issue:4

    Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Chloroq

2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
    JAMA network open, 2020, 04-24, Volume: 3, Issue:4

    Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Chloroq

2020
An open-label cluster-randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC)-Protocol publication.
    European journal of clinical investigation, 2020, Volume: 50, Issue:7

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
    Trials, 2020, Jul-08, Volume: 21, Issue:1

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therap

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
[Chloroquine phosphate: therapeutic drug for COVID-19].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2020, Apr-30, Volume: 40, Issue:4

    Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dr

2020
Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
    Trials, 2020, Dec-04, Volume: 21, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Case-Control Studie

2020
Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection.
    Pathogens and global health, 2021, Volume: 115, Issue:4

    Topics: Adult; Aged; Antimalarials; Antiparasitic Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Do

2021
An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients.
    Scientific reports, 2021, 04-27, Volume: 11, Issue:1

    Topics: Adult; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination;

2021

Other Studies

249 other studies available for chloroquine and 2019 Novel Coronavirus Disease

ArticleYear
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
    Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7

    Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiop

2020
Effect of drug metabolism in the treatment of SARS-CoV-2 from an entirely computational perspective.
    Scientific reports, 2021, 10-07, Volume: 11, Issue:1

    Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-1

2021
Melatonin mitigates Chloroquine-induced defects in porcine immature Sertoli cells.
    Theriogenology, 2022, Jan-01, Volume: 177

    Topics: Animals; Apoptosis; Autophagy; Chloroquine; COVID-19; COVID-19 Drug Treatment; Male; Melatonin; Phos

2022
Investigating interactions between chloroquine/hydroxychloroquine and their single enantiomers and angiotensin-converting enzyme 2 by a cell membrane chromatography method.
    Journal of separation science, 2022, Volume: 45, Issue:2

    Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Cell Membrane; Chloroquine; Chromatography, High

2022
Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect?
    Journal of medical virology, 2022, Volume: 94, Issue:3

    Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Mental Disorders; SARS-CoV-2

2022
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells.
    Emerging microbes & infections, 2022, Volume: 11, Issue:1

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chlorocebus aethiops; Chloroquine; COVID-

2022
Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.
    Pharmaceutical research, 2022, Volume: 39, Issue:1

    Topics: Administration, Inhalation; Aerosols; Algorithms; Cell Line; Chloroquine; COVID-19; Cytosol; Humans;

2022
Ab Initio Insight into the Interaction of Metal-Decorated Fluorinated Carbon Fullerenes with Anti-COVID Drugs.
    International journal of molecular sciences, 2022, Feb-21, Volume: 23, Issue:4

    Topics: Amides; Antiviral Agents; Chloroquine; COVID-19; Density Functional Theory; Drug Carriers; Drug Deli

2022
Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center.
    Rheumatology international, 2022, Volume: 42, Issue:10

    Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Female; Humans; Hydroxychloroqu

2022
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, 2022, Volume: 34, Issue:4

    Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2

2022
Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab.
    Scientific reports, 2022, 07-30, Volume: 12, Issue:1

    Topics: Chloroquine; Counterfeit Drugs; COVID-19; COVID-19 Drug Treatment; Developing Countries; Faith-Based

2022
Partition dimension of COVID antiviral drug structures.
    Mathematical biosciences and engineering : MBE, 2022, 07-15, Volume: 19, Issue:10

    Topics: Antiviral Agents; Chloroquine; COVID-19; Humans; SARS-CoV-2

2022
COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil.
    Journal of applied oral science : revista FOB, 2022, Volume: 30

    Topics: Brazil; Chloroquine; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Dentists; Humans; Inciden

2022
The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling.
    Drug metabolism and personalized therapy, 2023, 03-01, Volume: 38, Issue:1

    Topics: Adult; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Drug Interactions; Hu

2023
[The main aspects of the impact of the new coronavirus infection SARS-CoV-2 on the development of infertility in men].
    Urologiia (Moscow, Russia : 1999), 2022, Issue:5

    Topics: Chloroquine; COVID-19; Humans; Infertility; Lopinavir; Male; Pandemics; SARS-CoV-2

2022
[The main aspects of the impact of the new coronavirus infection SARS-CoV-2 on the development of infertility in men].
    Urologiia (Moscow, Russia : 1999), 2022, Issue:5

    Topics: Chloroquine; COVID-19; Humans; Infertility; Lopinavir; Male; Pandemics; SARS-CoV-2

2022
[The main aspects of the impact of the new coronavirus infection SARS-CoV-2 on the development of infertility in men].
    Urologiia (Moscow, Russia : 1999), 2022, Issue:5

    Topics: Chloroquine; COVID-19; Humans; Infertility; Lopinavir; Male; Pandemics; SARS-CoV-2

2022
[The main aspects of the impact of the new coronavirus infection SARS-CoV-2 on the development of infertility in men].
    Urologiia (Moscow, Russia : 1999), 2022, Issue:5

    Topics: Chloroquine; COVID-19; Humans; Infertility; Lopinavir; Male; Pandemics; SARS-CoV-2

2022
[The main aspects of the impact of the new coronavirus infection SARS-CoV-2 on the development of infertility in men].
    Urologiia (Moscow, Russia : 1999), 2022, Issue:5

    Topics: Chloroquine; COVID-19; Humans; Infertility; Lopinavir; Male; Pandemics; SARS-CoV-2

2022
[The main aspects of the impact of the new coronavirus infection SARS-CoV-2 on the development of infertility in men].
    Urologiia (Moscow, Russia : 1999), 2022, Issue:5

    Topics: Chloroquine; COVID-19; Humans; Infertility; Lopinavir; Male; Pandemics; SARS-CoV-2

2022
[The main aspects of the impact of the new coronavirus infection SARS-CoV-2 on the development of infertility in men].
    Urologiia (Moscow, Russia : 1999), 2022, Issue:5

    Topics: Chloroquine; COVID-19; Humans; Infertility; Lopinavir; Male; Pandemics; SARS-CoV-2

2022
[The main aspects of the impact of the new coronavirus infection SARS-CoV-2 on the development of infertility in men].
    Urologiia (Moscow, Russia : 1999), 2022, Issue:5

    Topics: Chloroquine; COVID-19; Humans; Infertility; Lopinavir; Male; Pandemics; SARS-CoV-2

2022
[The main aspects of the impact of the new coronavirus infection SARS-CoV-2 on the development of infertility in men].
    Urologiia (Moscow, Russia : 1999), 2022, Issue:5

    Topics: Chloroquine; COVID-19; Humans; Infertility; Lopinavir; Male; Pandemics; SARS-CoV-2

2022
Molecular mechanisms in chloroquine-exposed muscle cells elucidated by combined proteomic and microscopic studies.
    Neuropathology and applied neurobiology, 2023, Volume: 49, Issue:1

    Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Muscle Cells; Muscular Diseases; Proteins; P

2023
Challenges Based on Antiplasmodial and Antiviral Activities of 7-Chloro-4-aminoquinoline Derivatives.
    ChemMedChem, 2023, 04-03, Volume: 18, Issue:7

    Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19; Humans; Malaria; Plasmodium falciparum; SARS

2023
Affinity binding of COVID-19 drug candidates (chloroquine/hydroxychloroquine) and serum albumin: Based on photochemistry and molecular docking.
    Journal of photochemistry and photobiology. B, Biology, 2023, Volume: 240

    Topics: Antiviral Agents; Chloroquine; Computer Simulation; COVID-19; COVID-19 Drug Treatment; Humans; Hydro

2023
Novel Tetrahydroisoquinoline-Based Heterocyclic Compounds Efficiently Inhibit SARS-CoV-2 Infection
    Viruses, 2023, 02-11, Volume: 15, Issue:2

    Topics: Antiviral Agents; Chloroquine; COVID-19; Heterocyclic Compounds; Humans; Hydroxychloroquine; Pandemi

2023
Cardiotoxicity of chloroquine and hydroxychloroquine through mitochondrial pathway.
    BMC pharmacology & toxicology, 2023, 04-21, Volume: 24, Issue:1

    Topics: Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochromes c; Humans; Hydroxychloro

2023
Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020.
    Naunyn-Schmiedeberg's archives of pharmacology, 2023, Volume: 396, Issue:12

    Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug-Related Side E

2023
Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress.
    Archives of toxicology, 2023, Volume: 97, Issue:10

    Topics: Animals; Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Hydroxychloroquine; Mice; O

2023
A survey of chloroquine use for prevention and treatment of COVID-19 in Nigeria.
    African health sciences, 2023, Volume: 23, Issue:1

    Topics: Adult; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Female; Humans; Male

2023
Drug-induced phospholipidosis is not correlated with the inhibition of SARS-CoV-2 - inhibition of SARS-CoV-2 is cell line-specific.
    Frontiers in cellular and infection microbiology, 2023, Volume: 13

    Topics: Antiviral Agents; Cell Line; Chloroquine; COVID-19; Fluoxetine; Humans; SARS-CoV-2; Tilorone

2023
The COVID-19 and chloroquine infodemic: Cross-sectional observational study of content analysis on YouTube.
    PloS one, 2023, Volume: 18, Issue:9

    Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Female; Humans; Infodemic;

2023
Synthesis, docking studies and biological evaluation of 1H-1,2,3-triazole-7-chloroquinoline derivatives against SARS-CoV-2.
    Bioorganic chemistry, 2023, Volume: 141

    Topics: Antimalarials; Chloroquine; COVID-19; Humans; Molecular Docking Simulation; Protein Binding; Quinoli

2023
Real-Life Data on Hydroxychloroquine or Chloroquine with or Without Azithromycin in COVID-19 Patients: A Retrospective Analysis in Brazil.
    Arquivos brasileiros de cardiologia, 2023, Volume: 120, Issue:9

    Topics: Aged; Arrhythmias, Cardiac; Azithromycin; Brazil; Chloroquine; Cohort Studies; COVID-19; COVID-19 Dr

2023
QSPR/QSAR analysis of some eccentricity based topological descriptors of antiviral drugs used in COVID-19 treatment via $ \\mathscr{D}\\varepsilon $- polynomials.
    Mathematical biosciences and engineering : MBE, 2023, 09-05, Volume: 20, Issue:9

    Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Quantitative St

2023
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
More than 80 clinical trials launch to test coronavirus treatments.
    Nature, 2020, Volume: 578, Issue:7795

    Topics: Adenosine Monophosphate; Alanine; Animals; Anti-HIV Agents; Betacoronavirus; China; Chloroquine; Cli

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
    Revue medicale suisse, 2020, Mar-11, Volume: 16, Issue:685

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Pandemics;

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Advance of promising targets and agents against COVID-19 in China.
    Drug discovery today, 2020, Volume: 25, Issue:5

    Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus;

2020
Insights from nanomedicine into chloroquine efficacy against COVID-19.
    Nature nanotechnology, 2020, Volume: 15, Issue:4

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; COVID

2020
Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
    Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2020, Volume: 19, Issue:2

    Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus

2020
Chloroquine and COVID-19, where do we stand?
    Medecine et maladies infectieuses, 2020, Volume: 50, Issue:3

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Pandemics;

2020
Race to find COVID-19 treatments accelerates.
    Science (New York, N.Y.), 2020, 03-27, Volume: 367, Issue:6485

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin

2020
Race to find COVID-19 treatments accelerates.
    Science (New York, N.Y.), 2020, 03-27, Volume: 367, Issue:6485

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin

2020
Race to find COVID-19 treatments accelerates.
    Science (New York, N.Y.), 2020, 03-27, Volume: 367, Issue:6485

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin

2020
Race to find COVID-19 treatments accelerates.
    Science (New York, N.Y.), 2020, 03-27, Volume: 367, Issue:6485

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin

2020
Chloroquine in COVID-19: the evidence.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Mar-31, Volume: 90, Issue:1

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO

2020
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
    Annals of internal medicine, 2020, 06-02, Volume: 172, Issue:11

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Reposi

2020
Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.
    Rheumatology international, 2020, Volume: 40, Issue:5

    Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Betacoronavirus; Chloroquine;

2020
Combating COVID-19 with Chloroquine.
    Journal of molecular cell biology, 2020, 05-18, Volume: 12, Issue:4

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Endocytosis; Huma

2020
To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.
    Annals of the rheumatic diseases, 2020, Volume: 79, Issue:5

    Topics: Adenosine Monophosphate; Alanine; Antimalarials; Betacoronavirus; Chloroquine; Coronavirus; Coronavi

2020
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
    The American journal of tropical medicine and hygiene, 2020, Volume: 102, Issue:5

    Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatme

2020
COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?
    American journal of ophthalmology, 2020, Volume: 213

    Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; H

2020
What is the role of rheumatologists in the era of COVID-19?
    Autoimmunity reviews, 2020, Volume: 19, Issue:6

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimalarials; Azetidines; Betacoronavir

2020
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Amino Acid Sequence; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxy

2020
Chloroquine for COVID-19 Infection.
    Drug safety, 2020, Volume: 43, Issue:5

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pan

2020
Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes.
    Revista da Sociedade Brasileira de Medicina Tropical, 2020, Volume: 53

    Topics: Betacoronavirus; Chloroquine; Clinical Studies as Topic; Coronavirus Infections; COVID-19; Humans; P

2020
Chloroquine and hydroxychloroquine in covid-19.
    BMJ (Clinical research ed.), 2020, 04-08, Volume: 369

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO

2020
Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.
    Nature medicine, 2020, Volume: 26, Issue:5

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fear; Human

2020
Can prophylactic drugs keep fragile health systems running?
    Science (New York, N.Y.), 2020, 04-10, Volume: 368, Issue:6487

    Topics: Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine;

2020
Regulators split on antimalarials for COVID-19.
    Lancet (London, England), 2020, 04-11, Volume: 395, Issue:10231

    Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Approval; Europe

2020
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
    Bioscience trends, 2020, May-21, Volume: 14, Issue:2

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Drug Evaluation during the Covid-19 Pandemic.
    The New England journal of medicine, 2020, Jun-11, Volume: 382, Issue:24

    Topics: Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 D

2020
Chloroquine as a prophylactic agent against COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:6

    Topics: Animals; Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Chlorocebus aethiops; Chlor

2020
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infec

2020
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:10

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:10

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:10

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:10

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:10

    Topics: Betacoronavirus; Chloroquine; Contact Tracing; Coronavirus Infections; COVID-19; COVID-19 Drug Treat

2020
COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
    Molecules (Basel, Switzerland), 2020, Apr-16, Volume: 25, Issue:8

    Topics: Antimalarials; Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Cardiotoxicity; Chloroquine;

2020
Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?
    Annals of the rheumatic diseases, 2021, Volume: 80, Issue:2

    Topics: Antimalarials; Antiviral Agents; Chloroquine; COVID-19; Humans; Hydroxychloroquine; Pandemics; SARS-

2021
Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19).
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:10

    Topics: Aged; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; COVID-19; Delivery of Health C

2020
Is GSK3β a molecular target of chloroquine treatment against COVID-19?
    Drug discoveries & therapeutics, 2020, May-06, Volume: 14, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; C

2020
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.
    The American journal of tropical medicine and hygiene, 2020, Volume: 102, Issue:6

    Topics: Antimalarials; Antirheumatic Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; C

2020
Some drugs for COVID-19.
    The Medical letter on drugs and therapeutics, 2020, 04-06, Volume: 62, Issue:1595

    Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Angiotensin Receptor Antagonists; Angiote

2020
Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals.
    Drug discovery today, 2020, Volume: 25, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Aquatic Organisms; Biological Products; Chloroqu

2020
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Research in social & administrative pharmacy : RSAP, 2021, Volume: 17, Issue:2

    Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Interactions; D

2021
Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019.
    JAMA network open, 2020, 04-24, Volume: 3, Issue:4

    Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroqu

2020
Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.
    Annals of clinical microbiology and antimicrobials, 2020, Apr-24, Volume: 19, Issue:1

    Topics: Adult; Betacoronavirus; Chloroquine; Clarithromycin; Colombia; Coronavirus Infections; COVID-19; COV

2020
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
    Archives of cardiovascular diseases, 2020, Volume: 113, Issue:5

    Topics: Azithromycin; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-1

2020
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations;

2020
Chloroquine hype is derailing the search for coronavirus treatments.
    Nature, 2020, Volume: 580, Issue:7805

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene.
    Clinical chemistry and laboratory medicine, 2020, 06-25, Volume: 58, Issue:7

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Female; Glucosephosphate Dehydrogena

2020
COVID-19: an update on diagnostic and therapeutic approaches.
    BMB reports, 2020, Volume: 53, Issue:4

    Topics: Betacoronavirus; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVI

2020
Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2020, Volume: 20, Issue:7

    Topics: Adult; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combin

2020
Thoughts on COVID-19 and autoimmune diseases.
    Lupus science & medicine, 2020, Volume: 7, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Azetidines; Betacoronavirus; Chloroquine; Co

2020
Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?
    Medical hypotheses, 2020, Volume: 140

    Topics: Africa South of the Sahara; Anti-Inflammatory Agents; Antigen Presentation; Antimalarials; Antiviral

2020
Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev
    Annals of the rheumatic diseases, 2021, Volume: 80, Issue:2

    Topics: Antiviral Agents; Chloroquine; COVID-19; Humans; Hydroxychloroquine; SARS-CoV-2

2021
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Circulation. Arrhythmia and electrophysiology, 2020, Volume: 13, Issue:6

    Topics: Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroqui

2020
Internet Searches for Unproven COVID-19 Therapies in the United States.
    JAMA internal medicine, 2020, 08-01, Volume: 180, Issue:8

    Topics: Betacoronavirus; Chloroquine; Consumer Health Information; Coronavirus Infections; COVID-19; COVID-1

2020
Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.
    European heart journal. Cardiovascular pharmacotherapy, 2020, 07-01, Volume: 6, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
    British journal of clinical pharmacology, 2020, Volume: 86, Issue:6

    Topics: Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Hydr

2020
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
    European journal of clinical investigation, 2020, Volume: 50, Issue:6

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Chloroquine; Coronavirus Infec

2020
COVID-19 and Depression.
    Clinical therapeutics, 2020, Volume: 42, Issue:6

    Topics: Anxiety; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Depression; Humans; Hydroxy

2020
[Potential harms associated with 4-aminoquinoline treatment].
    Lakartidningen, 2020, 04-23, Volume: 117

    Topics: Aminoquinolines; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infectio

2020
Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, 05-04, Volume: 192, Issue:18

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Hydroxychloroquine; Pa

2020
The COVID-19 Pandemic and Mayo Clinic Proceedings.
    Mayo Clinic proceedings, 2020, Volume: 95, Issue:5

    Topics: Adrenal Cortex Hormones; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors;

2020
Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19.
    Drug discovery today, 2020, Volume: 25, Issue:7

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Reposi

2020
COVID-19: an unexpected indication for anti-rheumatic therapies?
    Rheumatology (Oxford, England), 2020, 06-01, Volume: 59, Issue:6

    Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Betacoronavirus; Ch

2020
COVID-19 and toxicity from potential treatments: Panacea or poison.
    Emergency medicine Australasia : EMA, 2020, Volume: 32, Issue:4

    Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVI

2020
Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.
    Heart rhythm, 2020, Volume: 17, Issue:9

    Topics: Aged, 80 and over; Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; CO

2020
Chloroquine for COVID-19: rationale, facts, hopes.
    Critical care (London, England), 2020, May-08, Volume: 24, Issue:1

    Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus

2020
Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.
    The Annals of pharmacotherapy, 2020, Volume: 54, Issue:8

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Emergencies

2020
Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:2

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Computational Biology; Coronavirus Infections; COVID

2020
Glucose-6-phosphate dehydrogenase deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine.
    American journal of hematology, 2020, Volume: 95, Issue:8

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Glucosephos

2020
[Chloroquine as a possible treatment for COVID-19].
    Nederlands tijdschrift voor geneeskunde, 2020, Mar-11, Volume: 164

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infect

2020
Chloroquine and hydroxychloroquine for COVID-19: A word of caution.
    Respirology (Carlton, Vic.), 2020, Volume: 25, Issue:7

    Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroqu

2020
[The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
    NTM, 2020, Volume: 28, Issue:2

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Bioethical Issues; Chloroquine;

2020
In Vitro Data of Current Therapies for SARS-CoV-2.
    Current medicinal chemistry, 2020, Volume: 27, Issue:27

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID

2020
Identification of Falsified Chloroquine Tablets in Africa at the Time of the COVID-19 Pandemic.
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:1

    Topics: Betacoronavirus; Cameroon; Chloroquine; Chromatography, High Pressure Liquid; Chromatography, Thin L

2020
Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
    Clinics (Sao Paulo, Brazil), 2020, Volume: 75

    Topics: Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 D

2020
Non-evidenced based treatment: An unintended cause of morbidity and mortality related to COVID-19.
    The American journal of emergency medicine, 2021, Volume: 39

    Topics: Chloroquine; COVID-19; Drugs, Chinese Herbal; Evidence-Based Medicine; Global Health; Humans; Methan

2021
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
    Medical hypotheses, 2020, Volume: 142

    Topics: Aged; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dieta

2020
An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.
    Research in social & administrative pharmacy : RSAP, 2021, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Azithromycin; Chloroquine; Cohort Studies; COVID-19; COVID-19 Drug Treatmen

2021
Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam.
    British journal of pharmacology, 2020, Volume: 177, Issue:21

    Topics: Animals; Arrhythmias, Cardiac; Benzodiazepinones; Cardiotoxicity; Chloroquine; Clonazepam; Coronavir

2020
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020, Volume: 26, Issue:9

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
    Medicina intensiva, 2020, Volume: 44, Issue:8

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Decision-

2020
Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
    JAMA internal medicine, 2020, 09-01, Volume: 180, Issue:9

    Topics: Access to Information; Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19

2020
Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19.
    Kidney international, 2020, Volume: 98, Issue:1

    Topics: Acute Kidney Injury; Autophagy; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Crit

2020
5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection.
    Medical hypotheses, 2020, Volume: 142

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronaviru

2020
COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
    American journal of ophthalmology, 2020, Volume: 216

    Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topi

2020
The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
    The primary care companion for CNS disorders, 2020, 05-21, Volume: 22, Issue:3

    Topics: Adrenal Cortex Hormones; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hyd

2020
COVID-19: Wait for a novel drug or act with the age old drug - Do we have a choice?
    Journal of infection and public health, 2020, Volume: 13, Issue:6

    Topics: Antimalarials; Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; Female; Humans; Indi

2020
Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia.
    Journal of medical virology, 2020, Volume: 92, Issue:11

    Topics: Antimalarials; Antiviral Agents; Chloroquine; Colombia; COVID-19; COVID-19 Drug Treatment; Drug Repo

2020
Navigating COVID-19 in the developing world.
    Clinical rheumatology, 2020, Volume: 39, Issue:7

    Topics: Antirheumatic Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Delivery of He

2020
Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.
    JAMA, 2020, 06-23, Volume: 323, Issue:24

    Topics: Antihypertensive Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Utiliz

2020
[Acute respiratory distress syndrome secondary to SARS-CoV-2 infection in an infant].
    Revue des maladies respiratoires, 2020, Volume: 37, Issue:6

    Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Betacoronavirus;

2020
Death threats after a trial on chloroquine for COVID-19.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:6

    Topics: Betacoronavirus; Brazil; Chloroquine; Clinical Trials, Phase II as Topic; Coronavirus Infections; CO

2020
Safety fears over drug hyped to treat the coronavirus spark global confusion.
    Nature, 2020, Volume: 582, Issue:7810

    Topics: Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Global Health; Humans; Hydr

2020
Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.
    Medical hypotheses, 2020, Volume: 143

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Resist

2020
COVID-19 presenting with diarrhoea and hyponatraemia.
    BMJ case reports, 2020, Jun-07, Volume: 13, Issue:6

    Topics: Abdominal Pain; Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus In

2020
Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
    Autophagy, 2020, Volume: 16, Issue:12

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Autophagy; Chloroquine; COVID-19; COVID-19 Drug Treatmen

2020
Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
    Autophagy, 2020, Volume: 16, Issue:12

    Topics: Autophagy; Chloroquine; COVID-19; COVID-19 Drug Treatment; Endosomes; Humans; Hydrogen-Ion Concentra

2020
Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2.
    Archivos de cardiologia de Mexico, 2020, Volume: 90, Issue:Supl

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19;

2020
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous.
    Journal of clinical pharmacology, 2020, Volume: 60, Issue:8

    Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Culture; Endp

2020
Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
    Journal of the neurological sciences, 2020, 08-15, Volume: 415

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen

2020
Living evidence in response to controversies about the use of antimalarials in COVID-19.
    Revista espanola de cardiologia (English ed.), 2020, Volume: 73, Issue:8

    Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics;

2020
Potential of Flavonoid-Inspired Phytomedicines against COVID-19.
    Molecules (Basel, Switzerland), 2020, Jun-11, Volume: 25, Issue:11

    Topics: Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroqu

2020
Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
    Annals of internal medicine, 2020, 07-21, Volume: 173, Issue:2

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen

2020
Treatment strategies of hospitalized patients with coronavirus disease-19.
    Aging, 2020, 06-17, Volume: 12, Issue:12

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; China; Chloroquin

2020
Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy.
    Epilepsy research, 2020, Volume: 165

    Topics: Adolescent; Adult; Aged; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dr

2020
Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19.
    British journal of pharmacology, 2020, Volume: 177, Issue:21

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Delive

2020
Chloroquine and COVID-19: A western medical and scientific drift?
    European journal of internal medicine, 2020, Volume: 78

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
The many mechanisms of action of Chloroquine: to use or not to use (in COVID-19) that is the question.
    British journal of pharmacology, 2020, Volume: 177, Issue:15

    Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine;

2020
Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.
    The American journal of cardiology, 2020, 09-01, Volume: 130

    Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment

2020
US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020.
    JAMA internal medicine, 2020, 10-01, Volume: 180, Issue:10

    Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19;

2020
Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
    Cellular signalling, 2020, Volume: 73

    Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cyt

2020
Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
    Revista de saude publica, 2020, Volume: 54

    Topics: Antimalarials; Betacoronavirus; Chloroquine; Contraindications, Drug; Coronavirus Infections; COVID-

2020
Concentration-dependent mortality of chloroquine in overdose.
    eLife, 2020, 07-08, Volume: 9

    Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dru

2020
Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.
    Molecular medicine (Cambridge, Mass.), 2020, 07-08, Volume: 26, Issue:1

    Topics: Animals; Autophagosomes; Autophagy; Betacoronavirus; Caspase 1; Caspases, Initiator; Chloroquine; Co

2020
BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?
    Cell death & disease, 2020, 07-08, Volume: 11, Issue:7

    Topics: Africa; Antiviral Agents; BCG Vaccine; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-1

2020
Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?
    Annals of the rheumatic diseases, 2022, Volume: 81, Issue:8

    Topics: Antimalarials; Chloroquine; COVID-19; Fear; Humans; Hydroxychloroquine

2022
Response to: 'Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?' by Santos-Moreno
    Annals of the rheumatic diseases, 2022, Volume: 81, Issue:8

    Topics: Antimalarials; Chloroquine; COVID-19; Fear; Humans; Hydroxychloroquine

2022
QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2020, Volume: 59, Issue:2

    Topics: Age Distribution; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Coronavirus Inf

2020
Bacillus Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.
    Vaccine, 2020, 07-31, Volume: 38, Issue:35

    Topics: Aging; Antiviral Agents; BCG Vaccine; Chemoprevention; Chloroquine; Coronavirus Infections; COVID-19

2020
Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2020, 04-02, Volume: 110, Issue:5

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen

2020
Trained innate immunity, COVID-19 therapeutic dilemma, and fake science.
    Clinics (Sao Paulo, Brazil), 2020, Volume: 75

    Topics: BCG Vaccine; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-1

2020
Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
    Annals of internal medicine, 2020, 08-18, Volume: 173, Issue:4

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Association between detectable SARS-COV-2 RNA in anal swabs and disease severity in patients with coronavirus disease 2019.
    Journal of medical virology, 2021, Volume: 93, Issue:2

    Topics: Adult; Anal Canal; Antiviral Agents; C-Reactive Protein; Chloroquine; COVID-19; COVID-19 Testing; Fe

2021
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
    Antiviral research, 2020, Volume: 181

    Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Berberine; Betacoronavirus; Chlorocebus

2020
Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns.
    Kardiologia polska, 2020, 08-25, Volume: 78, Issue:7-8

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.
    SLAS discovery : advancing life sciences R & D, 2020, Volume: 25, Issue:10

    Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, H

2020
Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
    Expert review of anti-infective therapy, 2021, Volume: 19, Issue:1

    Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; SARS

2021
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.
    Nature, 2020, Volume: 585, Issue:7826

    Topics: Animals; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronavirus Infections; COVI

2020
COVID-19 and hydroxychloroquine: Let the available data speak for themselves.
    European journal of internal medicine, 2020, Volume: 80

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Journal of nanoscience and nanotechnology, 2020, 12-01, Volume: 20, Issue:12

    Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Bin

2020
Chloroquine for Covid 19: introducing drug repurposing to medical students.
    International journal of medical education, 2020, Jul-24, Volume: 11

    Topics: Chloroquine; Coronavirus Infections; COVID-19; Drug Repositioning; Education, Medical; Humans; Pande

2020
Chloroquine in fighting COVID-19: good, bad, or both?
    Autophagy, 2020, Volume: 16, Issue:12

    Topics: Autophagy; Cardiovascular Diseases; China; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19

2020
Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2020, Volume: 30, Issue:6

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
    Annals of internal medicine, 2020, 09-01, Volume: 173, Issue:5

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen

2020
In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:3

    Topics: Amino Acid Motifs; Angiotensin-Converting Enzyme 2; Antiviral Agents; Azithromycin; Betacoronavirus;

2020
Editorial: Reconsidering anaphylaxis at the time of COVID-19 pandemic.
    Current opinion in allergy and clinical immunology, 2020, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Anaphylaxis; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents,

2020
Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.
    Journal of acquired immune deficiency syndromes (1999), 2020, 10-01, Volume: 85, Issue:2

    Topics: Adult; Antimalarials; Chloroquine; Chronic Disease; Coronavirus Infections; COVID-19; Drug Combinati

2020
[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
    Nederlands tijdschrift voor geneeskunde, 2020, 06-02, Volume: 164

    Topics: Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-

2020
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy.
    Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Antirheumatic Agents; Arthritis, Juvenile; Arthritis,

2021
Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.
    European journal of drug metabolism and pharmacokinetics, 2020, Volume: 45, Issue:6

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Severe arterial thromboembolism in patients with Covid-19.
    Journal of critical care, 2020, Volume: 60

    Topics: Aged, 80 and over; Blood Coagulation; Blood Coagulation Disorders; Chloroquine; COVID-19; COVID-19 D

2020
Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Journal of virology, 2020, 10-14, Volume: 94, Issue:21

    Topics: A549 Cells; Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Chlorpromazine; Coronavirus Inf

2020
Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out.
    European journal of internal medicine, 2020, Volume: 80

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Glucosephos

2020
New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine.
    International journal of molecular sciences, 2020, Aug-14, Volume: 21, Issue:16

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Envelope Proteins; Coronavirus Infection

2020
Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
    Annals of internal medicine, 2020, 10-06, Volume: 173, Issue:7

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
How to follow-up a patient who received tocilizumab in severe COVID-19: a case report.
    European journal of medical research, 2020, Aug-27, Volume: 25, Issue:1

    Topics: Adult; Antibodies, Monoclonal, Humanized; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus In

2020
Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig
    Annals of the rheumatic diseases, 2023, Volume: 82, Issue:5

    Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; France; Hospitalization; Humans; Hydroxychloroquine;

2023
Signal amplification by reversible exchange for COVID-19 antiviral drug candidates.
    Scientific reports, 2020, 08-31, Volume: 10, Issue:1

    Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Disco

2020
The influence of bitter-taste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19.
    Clinics (Sao Paulo, Brazil), 2020, Volume: 75

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Obe

2020
Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.
    Jornal brasileiro de nefrologia, 2020, Aug-26, Volume: 42, Issue:2 suppl 1

    Topics: Antimalarials; Brazil; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Human

2020
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.
    PLoS medicine, 2020, Volume: 17, Issue:9

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.
    European journal of clinical investigation, 2020, Volume: 50, Issue:11

    Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans;

2020
SARS-CoV-2 and hepatitis.
    Journal of gastrointestinal and liver diseases : JGLD, 2020, Sep-09, Volume: 29, Issue:3

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Betacoronavirus; Chemical and D

2020
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
    Toxicology and applied pharmacology, 2020, 11-01, Volume: 406

    Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Computer Simulation; Coronavirus Infec

2020
Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2020, Volume: 79

    Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Autophagy; Betacoronaviru

2020
Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
    Medicine, 2020, Sep-11, Volume: 99, Issue:37

    Topics: Anti-Infective Agents; Betacoronavirus; Chloroquine; Comorbidity; Coronavirus Infections; COVID-19;

2020
Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.
    BMJ open, 2020, 09-17, Volume: 10, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Cli

2020
Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes.
    BMB reports, 2020, Volume: 53, Issue:10

    Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Cell Differentiation

2020
Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
    Journal of proteome research, 2020, 11-06, Volume: 19, Issue:11

    Topics: Betacoronavirus; Catalytic Domain; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; CO

2020
Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2020, Volume: 40, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Child; Child, Prescho

2020
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:3

    Topics: Adult; Aged; Antimalarials; Cardiovascular Diseases; Chloroquine; COVID-19; COVID-19 Drug Treatment;

2021
Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.
    Biomolecules, 2020, 09-21, Volume: 10, Issue:9

    Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Viral; Antigen-Antibo

2020
Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?
    Central European journal of public health, 2020, Volume: 28, Issue:3

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therap

2020
Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 101

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Fe

2020
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:6

    Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatme

2020
A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2.
    Signal transduction and targeted therapy, 2020, 10-03, Volume: 5, Issue:1

    Topics: Animals; Antiviral Agents; Betacoronavirus; Biological Products; Bufanolides; Cardiac Glycosides; Ce

2020
Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 11-03, Volume: 117, Issue:44

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; CO

2020
Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis.
    Pharmacological reports : PR, 2020, Volume: 72, Issue:6

    Topics: Antiviral Agents; Binding Sites; Chloroquine; Ciprofloxacin; Coronavirus 3C Proteases; COVID-19; COV

2020
Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021, Volume: 27, Issue:2

    Topics: Aged; Aged, 80 and over; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; Hospital Mortality;

2021
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Antiviral research, 2020, Volume: 184

    Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimalarials; Antiviral Agents; Chlorocebus aeth

2020
Mean platelet volume/platelet count ratio predicts severe pneumonia of COVID-19.
    Journal of clinical laboratory analysis, 2021, Volume: 35, Issue:1

    Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment

2021
Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study.
    Journal of medical Internet research, 2020, 11-20, Volume: 22, Issue:11

    Topics: Adenosine Monophosphate; Alanine; Azithromycin; Chloroquine; Communication; Coronavirus Infections;

2020
Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
    Scientific reports, 2020, 11-05, Volume: 10, Issue:1

    Topics: Chloroquine; Cohort Studies; Coronavirus Infections; COVID-19; Female; Heart; Humans; Hydroxychloroq

2020
COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.
    Rheumatology (Oxford, England), 2021, 02-01, Volume: 60, Issue:2

    Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude to Health; Biological Products; Chloroq

2021
Cutaneous eruption in COVID-19-infected patients in Thailand: An observational descriptive study.
    The Journal of dermatology, 2021, Volume: 48, Issue:1

    Topics: Adult; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Eru

2021
Acute Guillain-Barré polyradiculoneuritis indicative of COVID-19 infection: a case report.
    The Pan African medical journal, 2020, Volume: 35, Issue:Suppl 2

    Topics: Adult; Atrial Fibrillation; Azithromycin; Betacoronavirus; Chloroquine; Clinical Laboratory Techniqu

2020
Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions.
    CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:2

    Topics: Action Potentials; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Chloroquine; COVID-19; COVI

2021
Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science.
    Medical anthropology quarterly, 2020, Volume: 34, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Anthropology, Medical; Antimalarials; Antiviral Agents; Chloroqu

2020
Composition analysis of falsified chloroquine phosphate samples seized during the COVID-19 pandemic.
    Journal of pharmaceutical and biomedical analysis, 2021, Feb-05, Volume: 194

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Chloroquine; Chromatography, High Pressure L

2021
Could Artesunate Have a Positive Effect on the Neurological Complications Related to Infection When It Is Used in the Treatment of COVID-19?
    ACS chemical neuroscience, 2020, 12-16, Volume: 11, Issue:24

    Topics: Antiviral Agents; Artemisinins; Central Nervous System Diseases; Chloroquine; COVID-19; COVID-19 Dru

2020
COVID-19 and Cardiac Concerns for Psychiatric Patients.
    The primary care companion for CNS disorders, 2020, 12-03, Volume: 22, Issue:6

    Topics: Antidepressive Agents; Antiviral Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular

2020
Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with chloroquine and rifampin.
    The Pan African medical journal, 2020, Volume: 35, Issue:Suppl 2

    Topics: Adult; Antimalarials; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Diagnosis, D

2020
Gender differences in treatment of Coronavirus Disease-2019.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Dec-03, Volume: 90, Issue:4

    Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Amides; Antimalarials; Antiviral Agents; Cardiovascul

2020
Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021, Jan-01, Volume: 1162

    Topics: Angiotensin-Converting Enzyme 2; Antimalarials; Binding, Competitive; Cell Membrane; Chloroquine; Ch

2021
Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; H

2020
Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2020, Volume: 40, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Chloroquine; Comorbidity; COVID

2020
Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adult; Aged; Blood Coagulation; Chloroquine; Coinfection; Comorbidity; Cough; COVID-19; COVID-19 Dru

2020
QTc Prolongation in COVID-19 Patients Using Chloroquine.
    Cardiovascular toxicology, 2021, Volume: 21, Issue:4

    Topics: Aged; Chloroquine; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Female; H

2021
Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience.
    Advances in respiratory medicine, 2020, Volume: 88, Issue:6

    Topics: Adult; Antiviral Agents; Case-Control Studies; Chloroquine; COVID-19; COVID-19 Drug Treatment; Femal

2020
COVID-19 infection in known epileptic and non-epileptic children: what is the place of chloroquine sulfate? (a case report).
    The Pan African medical journal, 2020, Volume: 37

    Topics: Adolescent; Child; Chloroquine; COVID-19; COVID-19 Drug Treatment; Electroencephalography; Epilepsy;

2020
[Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients].
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2021, Volume: 34, Issue:2

    Topics: Aged, 80 and over; Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; F

2021
Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism.
    Molecules (Basel, Switzerland), 2021, Jan-28, Volume: 26, Issue:3

    Topics: Angiotensin-Converting Enzyme 2; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychlo

2021
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum
    Journal of pharmaceutical and biomedical analysis, 2021, Mar-20, Volume: 196

    Topics: Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Chloroquine; Ch

2021
Cardiac arrhythmias in COVID-19 patients: A combination of viral comorbidities and pro-arrhythmic drug interactions.
    The American journal of emergency medicine, 2021, Volume: 48

    Topics: Angiotensin-Converting Enzyme 2; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithro

2021
COVID-19 infection in pediatric subjects: study of 36 cases in Conakry.
    The Pan African medical journal, 2020, Volume: 37, Issue:Suppl 1

    Topics: Adolescent; Asymptomatic Infections; Azithromycin; Child; Child, Preschool; Chloroquine; COVID-19; C

2020
Determining available strategies for prevention and therapy: Exploring COVID‑19 from the perspective of ACE2 (Review).
    International journal of molecular medicine, 2021, Volume: 47, Issue:4

    Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Cardiovascular Diseases; Chloroquine; COVID-19; H

2021
Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities.
    BMC medical research methodology, 2021, 02-26, Volume: 21, Issue:1

    Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; An

2021
Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.
    Virology journal, 2021, 02-27, Volume: 18, Issue:1

    Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Cell Survival; Chloro

2021
Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020.
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2021, Volume: 26, Issue:9

    Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine

2021
COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
    The Journal of pharmacology and experimental therapeutics, 2021, Volume: 377, Issue:2

    Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromyc

2021
Extracorporeal cardiopulmonary resuscitation for severe chloroquine intoxication in a child - a case report.
    Scandinavian journal of trauma, resuscitation and emergency medicine, 2021, Mar-15, Volume: 29, Issue:1

    Topics: Adolescent; Antimalarials; Cardiopulmonary Resuscitation; Chloroquine; COVID-19; COVID-19 Drug Treat

2021
Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2.
    Nature communications, 2021, 03-09, Volume: 12, Issue:1

    Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dru

2021
Heme oxygenase-1 inducer hemin does not inhibit SARS-CoV-2 virus infection.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 137

    Topics: Animals; Antiviral Agents; Cell Line; Cells, Cultured; Chlorocebus aethiops; Chloroquine; COVID-19;

2021
Management of Chloroquine and Hydroxychloroquine Poisoning: Do Not Miss the Time of Tracheal Intubation and Mechanical Ventilation.
    The western journal of emergency medicine, 2021, 01-11, Volume: 22, Issue:2

    Topics: Chloroquine; COVID-19; Humans; Hydroxychloroquine; Intubation, Intratracheal; Respiration, Artificia

2021
Response to: "Management of Chloroquine and Hydroxychloroquine Poisoning: Do Not Miss the Time of Tracheal Intubation and Mechanical Ventilation".
    The western journal of emergency medicine, 2021, 01-11, Volume: 22, Issue:2

    Topics: Chloroquine; COVID-19; Humans; Hydroxychloroquine; Intubation, Intratracheal; Respiration, Artificia

2021
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
    BMC infectious diseases, 2021, Apr-26, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treat

2021
Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2.
    Viruses, 2021, 04-09, Volume: 13, Issue:4

    Topics: A549 Cells; Animals; Caco-2 Cells; Cell Line; Cell Survival; Chlorocebus aethiops; Chloroquine; Colo

2021
Integrative web-based analysis of omics data for study of drugs against SARS-CoV-2.
    Scientific reports, 2021, 05-24, Volume: 11, Issue:1

    Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Cell Line; Chloroquine; COVID-19; COVID-19 Drug T

2021
Toward a Coronavirus Knowledge Graph.
    Genes, 2021, 06-29, Volume: 12, Issue:7

    Topics: Chloroquine; Computer Graphics; COVID-19; Databases, Factual; Hemorrhagic Fever, Ebola; Humans; Hydr

2021
Prophylactic and therapeutic potential of selected immunomodulatory agents from Ayurveda against coronaviruses amidst the current formidable scenario: an
    Journal of biomolecular structure & dynamics, 2022, Volume: 40, Issue:20

    Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Chloroquine; COVID-19; Ellagic Acid; Glycoprotein

2022
Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.
    PLoS pathogens, 2021, Volume: 17, Issue:7

    Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Cell Line; Chlorocebu

2021
Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
    Medicine, 2021, Jul-16, Volume: 100, Issue:28

    Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; D

2021
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19.
    The pharmacogenomics journal, 2021, Volume: 21, Issue:6

    Topics: Africa South of the Sahara; Chloroquine; COVID-19; COVID-19 Drug Treatment; Databases, Genetic; Gene

2021
SARS-CoV-2 attenuates corticosteroid sensitivity by suppressing DUSP1 expression and activating p38 MAPK pathway.
    European journal of pharmacology, 2021, Oct-05, Volume: 908

    Topics: Adult; Aged; Case-Control Studies; Cells, Cultured; Chloroquine; COVID-19; COVID-19 Drug Treatment;

2021
Risk factors for prolonged virus shedding of respiratory tract and fecal in adults with severe acute respiratory syndrome coronavirus-2 infection.
    Journal of clinical laboratory analysis, 2021, Volume: 35, Issue:9

    Topics: Adult; Animals; Antiviral Agents; CD4 Lymphocyte Count; Chloroquine; COVID-19; Feces; Female; Humans

2021
No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not.
    PloS one, 2021, Volume: 16, Issue:8

    Topics: Aged; Antiviral Agents; Biomarkers; C-Reactive Protein; Case-Control Studies; Chloroquine; COVID-19;

2021